[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 198
1. Martin KJ, Patrick DR, Bissell MJ, Fournier MV: Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One; 2008 Aug 20;3(8):e2994
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The predictive genes were selected in a well-defined three dimensional (3D) cell culture model of non-malignant human mammary epithelial cell morphogenesis as down-regulated during breast epithelial cell acinar formation and cell cycle arrest.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2006;7(10):R101 [17076897.001]
  • [Cites] Cell Cycle. 2008 Jun 15;7(12):1851-5 [18583930.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Breast Cancer Res. 2003;5(1):23-6 [12559041.001]
  • [Cites] Science. 2003 Apr 11;300(5617):238 [12690165.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3425-9 [12810680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Breast Cancer Res. 2004;6(3):109-18 [15084231.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 [15701700.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):453-4 [17157784.001]
  • [Cites] Biochem Soc Trans. 2007 Feb;35(Pt 1):18-22 [17212581.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):111-8 [16098464.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1884-6 [16166198.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5923-8 [16585533.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7095-102 [16849555.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Mar;61(3):187-94 [17088071.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):309-15 [17384585.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Oncogene. 2008 Jul 10;27(30):4137-49 [18345025.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • (PMID = 18714348.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA064786; United States / NCI NIH HHS / CA / U54CA112970-01; United States / NCI NIH HHS / CA / U54CA126552; United States / NCI NIH HHS / CA / U54 CA126552; United States / NCI NIH HHS / CA / U54 CA112970; United States / NCI NIH HHS / CA / R01 CA064786
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2500166
  •  go-up   go-down


2. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K: Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res; 2009 Sep;7(9):1572-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serine protease inhibitor, Kazal type 1 (SPINK1) is expressed not only in normal human pancreatic acinar cells but also in a variety of pancreatic ductal neoplasms.
  • We first showed that SPINK1 induced proliferation of NIH 3T3 cells and pancreatic cancer cell lines.
  • To determine which pathway is the most important for cell growth, we further analyzed the effect of inhibitors.
  • To further analyze the clinical importance of SPINK1 in the development of pancreatic cancer, we examined the expression of SPINK1 and EGFR in pancreatic tubular adenocarcinomas and pancreatic intraepithelial neoplasm.
  • [MeSH-major] Carrier Proteins / pharmacology. Pancreatic Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Growth Processes / drug effects. Cell Line, Tumor. Fibroblasts / drug effects. Humans. Immunohistochemistry. MAP Kinase Signaling System / drug effects. Mice. NIH 3T3 Cells. Phosphorylation / drug effects


3. Klimstra DS: Nonductal neoplasms of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S94-112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonductal neoplasms of the pancreas.
  • Although the majority of pancreatic neoplasms are infiltrating ductal adenocarcinomas or other neoplasms with ductal differentiation, neoplasms with acinar, endocrine, mixed, or uncertain differentiation constitute a diverse and distinctive group.
  • The most common and best-characterized nonductal neoplasms are pancreatic endocrine neoplasm, acinar cell carcinoma, pancreatoblastoma, and solid pseudopapillary neoplasm.
  • This review details the clinical and pathologic features of these nonductal neoplasms, highlighting diagnostic criteria including the use of specific immunohistochemical stains to define the cellular differentiation of the neoplasms.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenoma, Islet Cell / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486055.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Sandal T, Valyi-Nagy K, Spencer VA, Folberg R, Bissell MJ, Maniotis AJ: Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. Am J Pathol; 2007 May;170(5):1739-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the relationship between chromatin organization and tumor phenotype, we used an established three-dimensional assay in which normal and malignant human breast cells can be easily distinguished by the morphology of the structures they make (acinus-like versus tumor-like, respectively).
  • Treatment of T4-2 breast cancer cells in three-dimensional culture with cAMP analogs or a phosphatidylinositol 3-kinase inhibitor not only reverted their phenotype from nonpolar to polar acinar-like structures but also enhanced chromatin sensitivity to AluI.
  • These experiments underscore the concept that modifying the tumor microenvironment can alter the organization of tumor cells and demonstrate that architecture and global chromatin organization are coupled and highly plastic.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1984 Jun 7-13;309(5968):552-6 [6203040.001]
  • [Cites] Exp Cell Res. 1983 Apr 15;145(1):57-62 [6303820.001]
  • [Cites] Science. 1985 Nov 8;230(4726):676-8 [2996144.001]
  • [Cites] Int J Cancer. 1986 Jun 15;37(6):831-6 [3710614.001]
  • [Cites] EMBO J. 1987 Aug;6(8):2337-42 [2822387.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):3908-12 [2836864.001]
  • [Cites] J Cell Sci. 1988 Jul;90 ( Pt 3):391-9 [3253289.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6560-4 [1697684.001]
  • [Cites] Lancet. 1991 Jan 19;337(8734):130-3 [1670786.001]
  • [Cites] Development. 1993 Dec;119(4):1079-91 [8306876.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):11-6 [7927891.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):612-8 [7525495.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2039-44 [8616848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):849-54 [9023345.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Blood. 1997 Oct 15;90(8):3073-81 [9376588.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2184-95 [9528790.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14711-6 [9843954.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Nature. 1998 Dec 3;396(6710):474-7 [9853756.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2275-9 [9856955.001]
  • [Cites] J Soc Biol. 2004;198(3):287-91 [15662946.001]
  • [Cites] BJU Int. 2005 Mar;95(4):655-9 [15705098.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1187-203 [15793298.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jul;129(7):884-92 [15974811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3752-7 [16505384.001]
  • [Cites] Lancet. 1984 Oct 20;2(8408):890-2 [6148619.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):164-9 [10646869.001]
  • [Cites] J Cell Sci. 2000 Mar;113 ( Pt 5):849-58 [10671374.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33920-8 [10944524.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:122-38 [12119272.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1494-503 [12359858.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1157-73 [12615960.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):121-6 [12829247.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35394-402 [12819211.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8827-36 [14695199.001]
  • [Cites] J Cell Biol. 2004 Feb 16;164(4):603-12 [14769856.001]
  • [Cites] Exp Cell Res. 2004 Aug 1;298(1):122-32 [15242767.001]
  • [Cites] J Biol Chem. 1968 Jul 10;243(13):3763-5 [4298072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3585-9 [1059147.001]
  • [CommentIn] Am J Pathol. 2007 Nov;171(5):1726-7; author reply 1727 [17982134.001]
  • (PMID = 17456778.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY010457; United States / NEI NIH HHS / EY / EY10457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; E0399OZS9N / Cyclic AMP; EC 3.1.21.- / DNA Restriction Enzymes
  • [Other-IDs] NLM/ PMC1854967
  •  go-up   go-down


5. Suzuki A, Sakaguchi T, Morita Y, Oishi K, Fukumoto K, Inaba K, Takehara Y, Baba S, Suzuki S, Konno H: Long-term survival after a repetitive surgical approach in a patient with acinar cell carcinoma of the pancreas and recurrent liver metastases: report of a case. Surg Today; 2010 Jul;40(7):679-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after a repetitive surgical approach in a patient with acinar cell carcinoma of the pancreas and recurrent liver metastases: report of a case.
  • Acinar cell carcinoma is a relatively rare malignant neoplasm, which represents 1%-2% of all pancreatic exocrine tumors.
  • This report concerns a case of a long-term survivor of metastatic acinar cell carcinoma who was successfully treated with repetitive surgery.
  • A 62-year-old man underwent a distal pancreatectomy for a pancreatic tumor, which was histologically diagnosed as an acinar cell carcinoma.
  • The tumor recurred in the liver three times within 41 months.
  • Although no consensus has been reached on surgery for metastatic acinar cell carcinoma, the current case has important implications for establishing an appropriate treatment strategy.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Metastasis. Reoperation. Survivors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JOP. 2007 Nov 09;8(6):783-9 [17993731.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] Surg Today. 2007;37(8):704-7 [17643220.001]
  • [Cites] Surg Today. 1996;26(5):357-60 [8726623.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):85-93 [3812876.001]
  • [Cites] Pancreas. 2001 Jul;23(1):109-12 [11451140.001]
  • [Cites] Surg Today. 1996;26(9):762-4 [8883259.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Pancreas. 2007 Mar;34(2):271-2 [17312470.001]
  • (PMID = 20582524.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Ohike N, Sato M, Hisayuki T, Imataka H, Sato S, Wada Y, Saito K, Takahashi M, Tajiri T, Kunimura T, Morohoshi T: Immunohistochemical analysis of nestin and c-kit and their significance in pancreatic tumors. Pathol Int; 2007 Sep;57(9):589-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to clarify the difference of expression of two stem cell markers, nestin and c-kit, among various pancreatic epithelial tumors and evaluate their utility.
  • Immunohistochemistry was done for 99 surgically resected pancreatic tumor specimens, including 20 ductal adenocarcinoma (DAC), two undifferentiated carcinomas (UC), 31 intraductal papillary-mucinous neoplasms (IPMN), six mucinous cystic neoplasms (MCN), five serous cystadenomas (SCA), six acinar cell carcinomas, two pancreatoblastoma (PB), eight solid-pseudopapillary neoplasms (SPN), and 19 endocrine neoplasms (EN).
  • These indicate that expression of two stem cell markers is different by tumor type, but the utility of judging direction or degree of differentiation and malignant grade on the basis of their expression status is suggested.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Immunoenzyme Techniques / methods. Intermediate Filament Proteins / analysis. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / analysis. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685930.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


7. Blume SW, Jackson NL, Frost AR, Grizzle WE, Shcherbakov OD, Choi H, Meng Z: Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. Exp Mol Pathol; 2010 Jun;88(3):341-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genes involved in the control of cell proliferation and survival (those genes most important to cancer pathogenesis) are often specifically regulated at the translational level, through RNA-protein interactions involving the 5'-untranslated region of the mRNA.
  • IGF1R is a proto-oncogene strongly implicated in human breast cancer, promoting survival and proliferation of tumor cells, as well as metastasis and chemoresistance.
  • We observe dramatic changes in the northwestern profile of non-malignant breast cells downregulating IGF1R expression in association with acinar differentiation in 3-D culture.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2028-45 [10950867.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):1-10 [10517338.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):18-22 [19106609.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2840-9 [19351773.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4192-201 [19435893.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1448-59 [19509240.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] Breast Cancer Res Treat. 2009 Nov;118(2):229-39 [19685287.001]
  • [Cites] Oncogene. 2010 Jan 14;29(2):251-62 [19838209.001]
  • [Cites] J Cell Biochem. 2010 May 15;110(2):531-44 [20432247.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4437-40 [10980620.001]
  • [Cites] Breast Cancer Res. 2000;2(3):170-5 [11250706.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20824-6 [11331271.001]
  • [Cites] Cancer Cell. 2002 May;1(4):339-53 [12086849.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2002;72:367-413 [12206457.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):11-6 [12209582.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Mol Cell Endocrinol. 2003 Feb 28;200(1-2):127-40 [12644306.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):5017-24 [14615489.001]
  • [Cites] Genes Dev. 1988 Feb;2(2):215-27 [3129338.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Jun 28;177(3):1113-20 [1711844.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Annu Rev Biochem. 1993;62:289-321 [8352591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11217-21 [8248231.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2463-9 [7758000.001]
  • [Cites] Exp Cell Res. 1997 Feb 1;230(2):284-92 [9024787.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Nucleic Acids Res. 2005;33(9):2962-79 [15914670.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1453-62 [16266891.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R18 [16584539.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):1-22 [16844299.001]
  • [Cites] RNA. 2006 Oct;12(10):1755-85 [16957278.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1636-44 [16953219.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):3165-75 [17296734.001]
  • [Cites] J Biol Chem. 2007 Aug 3;282(31):22513-24 [17545147.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(18):6265-78 [17620417.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2609-19 [18568074.001]
  • [Cites] J Cell Physiol. 2008 Oct;217(1):172-83 [18452152.001]
  • [Cites] J Biol Chem. 2008 Aug 22;283(34):23274-87 [18562319.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):381-406 [19016312.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10215-22 [19074889.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10238-46 [19074892.001]
  • [Cites] RNA Biol. 2009 Jan-Mar;6(1):84-9 [19106631.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 1998;27:407-45 [9646873.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:399-458 [9891789.001]
  • [Cites] Nat Cell Biol. 2008 Sep;10(9):1051-61 [19160485.001]
  • (PMID = 20233590.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108886-05; United States / NCI NIH HHS / CA / R01 CA108886; United States / NCI NIH HHS / CA / CA108886; United States / NCI NIH HHS / CA / R01 CA108886-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA-Binding Proteins; 0 / Trans-Activators
  • [Other-IDs] NLM/ NIHMS189588; NLM/ PMC2868104
  •  go-up   go-down


8. Alì G, Donati V, Loggini B, Servadio A, Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A, Fontanini G: Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol; 2008 Oct;39(10):1465-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, estrogen receptor beta expression was low or negative in 68.2% of solid subtypes, whereas it was high in 76.5% of nonmucinous bronchioloalveolar, in 69.4% of acinar, and in 61.2% of papillary patterns (P = .00004).
  • Furthermore, a strong association between estrogen receptor beta expression and tumor histologic grade was observed: estrogen receptor beta was highly expressed predominantly in well- and moderately differentiated tumors (P = .0014).
  • [MeSH-major] Adenocarcinoma / metabolism. Estrogen Receptor beta / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Dedifferentiation. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620727.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta
  •  go-up   go-down


9. Hruban RH, Maitra A, Goggins M: Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol; 2008;1(4):306-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on pancreatic intraepithelial neoplasia.
  • Pancreatic intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal adenocarcinoma of the pancreas.
  • The association of acinar-ductal metaplasia with PanIN lesions has led some to hypothesize that PanINs develop from acinar cells that undergo acinar-ductal metaplasia.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):622-5 [12697855.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):635-43 [11756558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]
  • [Cites] Cancer. 1979 Apr;43(4):1418-28 [445339.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1674-80 [15188160.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5417-22 [17000675.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5411-6 [17000674.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • (PMID = 18787611.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480542
  • [Keywords] NOTNLM ; Pancreatic cancer / epigenetics / genetics / intraepithelial neoplasm / metaplasia
  •  go-up   go-down


10. Cossu-Rocca P, Eble JN, Zhang S, Martignoni G, Brunelli M, Cheng L: Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol; 2006 Jun;19(6):780-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • End-stage renal disease is associated with an increased incidence of renal cell neoplasms.
  • These tumors often occur in kidneys with acquired cystic disease and are composed mainly of large eosinophilic cells arranged in solid, cribriform, acinar, or papillary patterns.
  • Each of the tumors was composed of large eosinophilic cells arranged in solid, acinar, or tubulocystic architecture.
  • Deposits of calcium oxalate crystals were present in each tumor.
  • Hale's colloidal stain showed a positive cytoplasmic reaction in one of the neoplasms.
  • Fluorescence in situ hybridization analysis showed no losses or gains of chromosomes 1, 2, 6, 10, or 17 in one tumor.
  • Eosinophilic renal cell tumors associated with acquired cystic disease have immunophenotypes and genetic profiles distinct from the renal cell neoplasms recognized in the current classification of renal cell neoplasia, and should be considered as a distinct clinicopathologic entity in the spectrum of renal cell neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. In Situ Hybridization, Fluorescence. Kidney Diseases, Cystic / pathology. Kidney Failure, Chronic / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aneuploidy. Biomarkers, Tumor / metabolism. Chromosomes, Human, 1-3. Chromosomes, Human, Pair 6. DNA, Neoplasm / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575398.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


11. Chen Y, Yu G, Ma D, Ni C, Zhu M: Microadenocarcinoma of the pancreas. Eur J Gastroenterol Hepatol; 2009 Dec;21(12):1373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Microadenocarcinoma (MA) of the pancreas is a rare kind of neoplasm, whose status as an independent tumor entity is still a matter of controversy.
  • Immunohistochemistry revealed that MA, though with a certain extent of epithelial differentiation, possesses a different immunological phenotype from those of ductal carcinoma, acinar cell carcinoma, and endocrine tumors.
  • Genetic analysis showed no abnormality of p53, K-ras, and beta-catenin, which were usually mutated in pancreatic ductal adenocarcinoma.
  • CONCLUSION: Therefore, we suggest that MA should be taken as an independent tumor entity rather than a kind of growth pattern, but a final decision should be reached after cautious differential diagnosis of other kinds of pancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916245.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Reis-Filho JS, Natrajan R, Vatcheva R, Lambros MB, Marchió C, Mahler-Araújo B, Paish C, Hodi Z, Eusebi V, Ellis IO: Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology; 2008 Jun;52(7):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
  • AIMS: Acinic cell carcinomas (ACCs) and secretory carcinomas (SCs) of the breast are rare, low-grade malignancies that preferentially affect young female patients.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Acinar Cell / genetics. Gene Rearrangement. In Situ Hybridization, Fluorescence. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Female. Humans

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462362.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


13. Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS: Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol; 2010 Apr;34(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
  • BACKGROUND: Pancreatic acinar cell carcinomas (ACCs) are clinically and pathologically distinct from pancreatic ductal adenocarcinomas (PDAs).
  • All cases showed significant evidence of both acinar and ductal differentiation, estimated to be at least 25% of the neoplastic cells, and 3 cases in addition had endocrine differentiation in more than 25% of cells.
  • Five cases were predominately acinar with intracellular and sometimes extracellular mucin ("mucinous acinar cell carcinoma" pattern).
  • Six cases seemed more mixed with areas recapitulating typical PDAs whereas the other portions of the tumors seemed akin to typical acinar cell carcinomas ("combined acinar and ductal" pattern).
  • CONCLUSION: Despite the early embryologic divergence of acinar and ductal cell lineages, rare pancreatic tumors have both acinar and ductal differentiation, usually predominantly the former.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucins / metabolism. Mutation. Neoplasms, Multiple Primary. New York / epidemiology. Pancreatectomy. Proto-Oncogene Proteins / genetics. Survival Rate. Virginia / epidemiology. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182344.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Mucins; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


14. Azúa-Romeo J, Sánchez-Garnica JC, Azúa-Blanco J, Tovar-Lázaro M: DNA quantification as prognostic factor in a case of acinar cell carcinoma of the parotid gland, diagnosed by FNA. Med Oral Patol Oral Cir Bucal; 2005 Aug-Oct;10(4):289-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA quantification as prognostic factor in a case of acinar cell carcinoma of the parotid gland, diagnosed by FNA.
  • Fine needle aspiration cytology was performed, diagnosing of compatible with acinar cell carcinoma, thus DNA quantification by image cytometry was carried out.
  • [MeSH-major] Carcinoma, Acinar Cell / genetics. Parotid Neoplasms / genetics
  • [MeSH-minor] Adult. Aneuploidy. Biopsy, Fine-Needle. DNA Replication. DNA, Neoplasm / analysis. Humans. Image Cytometry. Male. Neoplasm Invasiveness. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16056182.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


15. Folch-Puy E, Granell S, Dagorn JC, Iovanna JL, Closa D: Pancreatitis-associated protein I suppresses NF-kappa B activation through a JAK/STAT-mediated mechanism in epithelial cells. J Immunol; 2006 Mar 15;176(6):3774-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knowing that PAP I and IL-10 responses share several features, we have used a pancreatic acinar cell line (AR42J) to assess the extent to which their expression is reciprocally regulated, and whether the JAK/STAT and NF-kappaB signaling pathways are involved in the suppression of inflammation mediated by PAP I.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Epithelial Cells / metabolism. Lectins, C-Type / metabolism. NF-kappa B / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Active Transport, Cell Nucleus. Animals. Cell Line. Gene Expression Regulation. Interleukin-10 / genetics. Interleukin-10 / metabolism. Phosphotyrosine / metabolism. Protein Biosynthesis. Protein Kinase Inhibitors / pharmacology. RNA, Messenger / genetics. Rats. Signal Transduction / drug effects. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / pharmacology. Tyrphostins / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517747.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / NF-kappa B; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / Tumor Necrosis Factor-alpha; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; 0 / pancreatitis-associated protein; 130068-27-8 / Interleukin-10; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


16. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol; 2008 Jan;3(1):13-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Very recently, we have found a novel fusion product between the echinoderm microtubule-associated protein-like4 (EML4) and the anaplastic lymphoma kinase (ALK) in non-small cell lung cancers (NSCLCs).
  • METHODS: Using reverse transcription-polymerase chain reaction for EML4-ALK fusion mRNA, we investigated 149 lung adenocarcinomas, 48 squamous cell carcinomas, 3 large-cell neuroendocrine carcinomas, and 21 small-cell carcinomas.
  • Interestingly, all three variant 2 cases were acinar adenocarcinomas, the link being statistically significant (p = 0.00018).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Squamous Cell / pathology. Cell Cycle Proteins / genetics. Chromosome Inversion. Chromosomes, Human, Pair 2. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Male. Microtubule-Associated Proteins / genetics. Protein-Tyrosine Kinases / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166835.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / EML4-ALK fusion protein, human; 0 / Microtubule-Associated Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.21.- / EML4 protein, human; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


17. Go JH: A spindle cell predominant pancreatic solid-pseudopapillary tumor. Yonsei Med J; 2008 Aug 30;49(4):672-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A spindle cell predominant pancreatic solid-pseudopapillary tumor.
  • A hitherto unrecognized variant of solid-pseudopapillary tumor (SPT) of the pancreas is reported.
  • The tumor presented in the pancreatic tail of a 44-year-old female patient.
  • Histologically, the neoplasm was mostly composed of sheets of spindle cells.
  • The periphery of the tumor showed typical feature of SPT.
  • Immunohistochemically, the tumor cells were positive for vimentin, CD10, CD56, beta-catenin, and alpha1-antichymotrypsin, but negative for cytokeratin, chromogranin, synaptophysin and S-100 protein.
  • Ultrastructurally, the tumor showed a few acinar spaces with microvilli between tumor cells.
  • This case is peculiar in that the tumor did not show gross cystic change and predominantly consists of spindle shaped tumor cells, so may cause difficult diagnostic problem.
  • [MeSH-major] Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1361-71 [11023097.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):818-20 [12023593.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] JOP. 2006;7(1):131-6 [16407635.001]
  • [Cites] J Surg Oncol. 2004 Mar 15;85(4):193-8 [14991875.001]
  • (PMID = 18729314.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2615298
  •  go-up   go-down


18. Benkoël L, Bernard JP, Payan-Defais MJ, Crescence L, Franceschi C, Delmas M, Ouaissi M, Sastre B, Sahel J, Benoliel AM, Bongrand P, Silvy F, Gauthier L, Romagné F, Lombardo D, Mas E: Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues. Mol Cancer Ther; 2009 Feb;8(2):282-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues.
  • We have shown that the 16D10 antigen located on the mucin-like COOH-terminal domain of the feto-acinar pancreatic protein (FAPP) is expressed at the surface of human pancreatic tumor cell lines such as SOJ-6 cell line.
  • Furthermore, an in vivo study indicates that targeting this cell-membrane glycopeptide by the use of the monoclonal antibody (mAb) 16D10 inhibits the growth of SOJ-6 xenografts in nude mice.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Lipase / chemistry. Lipase / immunology. Pancreatic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Antibody Specificity. Antigens, Neoplasm / immunology. Electrophoresis, Polyacrylamide Gel. Female. Fluorescence. Frozen Sections. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Neoplasm Metastasis. Organ Specificity. Preoperative Care. Protein Structure, Tertiary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190122.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


19. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas; 2007 Jul;35(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society.
  • OBJECTIVES: Acinar cell carcinoma (ACC) of the pancreas is a rare tumor, and many aspects remain unclear because no large-scale clinical studies have been conducted.
  • RESULTS: Although ACC has been associated with advanced stage and poor prognosis, this tumor was resectable in 76.5% of the patients, and the 5-year survival rate after resection was favorable, being 43.9%.
  • [MeSH-major] Carcinoma, Acinar Cell / mortality. Pancreatic Neoplasms / mortality. Registries / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575544.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Hirota SK, Modolo F, Portela de Albuquerque MA, Lehn CN, Sugaya NN, Machado de Sousa SO, Paraiso Cavalcanti MG: Recurring acinic cell carcinoma of the buccal mucosa: a case report. Quintessence Int; 2007 Apr;38(4):289-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurring acinic cell carcinoma of the buccal mucosa: a case report.
  • A case of acinic cell adenocarcinoma of the left facial area of 10-years' duration in a 29-year-old man is presented.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Neoplasm Recurrence, Local. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432783.001).
  • [ISSN] 0033-6572
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Keratin-7; 0 / Keratin-8; 0 / Ki-67 Antigen; 0 / Vimentin
  •  go-up   go-down


21. Ferrés-Masó M, Sacilotto N, López-Rodas G, Dagorn JC, Iovanna JL, Closa D, Folch-Puy E: PAP1 signaling involves MAPK signal transduction. Cell Mol Life Sci; 2009 Jul;66(13):2195-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we describe the intracellular pathways triggered by PAP1 in a pancreatic acinar cell line.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Lectins, C-Type / metabolism. MAP Kinase Signaling System / physiology. Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Cell Line. Gene Expression Regulation, Enzymologic. Humans. Pancreas / cytology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Transcriptional Activation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1984;29(4):242-9 [6468771.001]
  • [Cites] Scand J Gastroenterol. 2004 Sep;39(9):870-81 [15513386.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1441-50 [12890698.001]
  • [Cites] Digestion. 1999 Jan-Feb;60(1):41-7 [9892797.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 1):G993-1002 [8997243.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):24173-80 [9727040.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):816-28 [10982776.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):614-8 [9403691.001]
  • [Cites] Nucleic Acids Res. 2004 Jun 24;32(11):e88 [15247321.001]
  • [Cites] J Surg Res. 2004 May 15;118(2):122-35 [15100001.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):808-16 [9516402.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3774-9 [16517747.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):7199-207 [14660681.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1525-33 [10550309.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1948-58 [18641332.001]
  • [Cites] Dig Dis Sci. 1999 Jun;44(6):1142-7 [10389686.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4041-6 [9814489.001]
  • [Cites] Neurobiol Aging. 2001 Jan-Feb;22(1):79-88 [11164279.001]
  • [Cites] Biochem J. 2006 Sep 15;398(3):431-7 [16776654.001]
  • [Cites] Nat Cell Biol. 2000 Dec;2(12):906-14 [11146655.001]
  • [Cites] Chromosoma. 2005 Jul;114(2):86-91 [15902482.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5686-90 [8621433.001]
  • [Cites] Eur J Biochem. 2004 Oct;271(19):3812-20 [15373827.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1452-64 [17133485.001]
  • [Cites] J Biol Chem. 1995 Sep 22;270(38):22417-21 [7545677.001]
  • [Cites] Arch Biochem Biophys. 1996 Jun 1;330(1):129-32 [8651687.001]
  • [Cites] Eur J Cell Biol. 2001 Feb;80(2):156-63 [11302520.001]
  • [Cites] Dig Dis Sci. 2003 Mar;48(3):459-64 [12757156.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(22):3525-44 [18668205.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):108-16 [15213626.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6508-16 [9343414.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):426-33 [11231317.001]
  • [Cites] Gut. 2007 Aug;56(8):1091-7 [17409121.001]
  • [Cites] J Surg Res. 2002 Jun 15;105(2):136-44 [12121700.001]
  • [Cites] Gut. 2005 Sep;54(9):1244-53 [15870231.001]
  • [Cites] Gene. 1988 Jul 30;67(2):271-7 [3169576.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • (PMID = 19434369.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / RNA, Messenger; 0 / pancreatitis-associated protein; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


22. Yamaue H: [Clinical characteristics of invasive ductal carcinomas of the pancreas according to the histological differentiation]. Nihon Rinsho; 2006 Jan;64 Suppl 1:48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Acinar Cell / pathology. Humans. Neoplasm Invasiveness / pathology. Prognosis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457220.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


23. Ou SH, Ziogas A, Zell JA: Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol; 2010 Apr;5(4):420-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The presence of signet-ring cell component has been described as a prominent feature of EML4-ALK positive non-small cell lung cancer.
  • Patients with primary SRC of the lung were significantly younger than patients with adenocarcinoma, with a significantly higher proportion of poorly differentiated tumor and stage IV disease.
  • CONCLUSIONS: Primary SRC of the lung is a rare subtype of adenocarcinoma, carries a worse prognosis when compared to adenocarcinoma and shares many of the recently identified clinicopathologic characteristics ascribed to EML4-ALK positive non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / epidemiology. Adenocarcinoma, Papillary / epidemiology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130484.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-54404
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


24. Man YG, Gardner WA: Bad seeds produce bad crops: a single stage-process of prostate tumor invasion. Int J Biol Sci; 2008 Aug 11;4(4):246-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bad seeds produce bad crops: a single stage-process of prostate tumor invasion.
  • It is a commonly held belief that prostate carcinogenesis is a multi-stage process and that tumor invasion is triggered by the overproduction of proteolytic enzymes.
  • This belief is consistent with data from cell cultures and animal models, whereas is hard to interpret several critical facts, including the presence of cancer in "healthy" young men and cancer DNA phenotype in morphologically normal prostate tissues.
  • These facts argue that alternative pathways may exist for prostate tumor invasion in some cases.
  • Since degradation of the basal cell layer is the most distinct sign of invasion, our recent studies have attempted to identify pre-invasive lesions with focal basal cell layer alterations.
  • Our studies revealed that about 30% of prostate cancer patients harbored normal appearing duct or acinar clusters with a high frequency of focal basal cell layer disruptions.
  • These focally disrupted basal cell layers had significantly reduced cell proliferation and tumor suppressor expression, whereas significantly elevated degeneration, apoptosis, and infiltration of immunoreactive cells.
  • In sharp contrast, associated epithelial cell had significantly elevated proliferation, expression of malignancy-signature markers, and physical continuity with invasive lesions.
  • Based on these and other findings, we have proposed that these normal appearing duct or acinar clusters are derived from monoclonal proliferation of genetically damaged stem cells and could progress directly to invasion through two pathways:.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Jul;78(1):46-9 [9662249.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):42-7 [9889056.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1):69-74 [10396288.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):103-18 [15530847.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):199-208 [15692763.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):30-7 [15722791.001]
  • [Cites] Cancer Detect Prev. 2005;29(2):161-9 [15829376.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Cancer Detect Prev. 2005;29(4):323-31 [16122886.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8583-6 [16204020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19093-6 [16361440.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2028-37 [16489002.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):164-71 [16804520.001]
  • [Cites] J Urol. 2006 Sep;176(3):1012-6 [16890681.001]
  • [Cites] Cancer Detect Prev. 2006;30(3):239-47 [16872754.001]
  • [Cites] Pathol Res Pract. 2006;202(9):651-62 [16842934.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:156-68 [12095941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5401-6 [12702759.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52 [12788977.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R231-41 [14580259.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):305-10 [14663472.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):47-56 [14751137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10721-5 [15249662.001]
  • [Cites] Cell. 2004 Aug 6;118(3):277-9 [15294153.001]
  • [Cites] Med Hypotheses. 2007;69(6):1340-57 [17493765.001]
  • [Cites] Med Hypotheses. 2008;70(2):387-408 [17658698.001]
  • [Cites] Semin Urol Oncol. 1999 Nov;17(4):187-98 [10632120.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5737-46 [17575140.001]
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7377-83 [11007896.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):44-9 [11144903.001]
  • [Cites] Cell Mol Life Sci. 2001 Jul;58(8):1150-8 [11529507.001]
  • [Cites] J Cell Physiol. 2001 Nov;189(2):189-96 [11598904.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1172-7 [12006534.001]
  • [Cites] Int J Biol Sci. 2008;4(4):246-58 [18725981.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):1-6 [18931648.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] J Cell Physiol. 2004 Nov;201(2):266-76 [15334661.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] Lab Invest. 1983 Aug;49(2):140-7 [6348406.001]
  • [Cites] Semin Thromb Hemost. 1986 Oct;12(4):294-307 [3024322.001]
  • [Cites] J Urol. 1987 Jan;137(1):53-6 [2432282.001]
  • [Cites] Hum Pathol. 1988 Jan;19(1):119-20 [3335387.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(5):375-81 [2035251.001]
  • [Cites] Prostate Suppl. 1992;4:71-7 [1374179.001]
  • [Cites] Lab Invest. 1994 Jan;70(1):6-22 [8302019.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2465-72 [7872668.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1995;5(1):1-77 [7549180.001]
  • [Cites] Hum Pathol. 1995 Dec;26(12):1291-2 [8522299.001]
  • [Cites] Prostate. 1996 Feb;28(2):98-106 [8604398.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Nat Med. 1997 Aug;3(8):927-30 [9256288.001]
  • [Cites] Pathologe. 1998 Jan;19(1):12-20 [9541938.001]
  • (PMID = 18725981.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02 PC051308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2519176
  • [Keywords] NOTNLM ; pre-invasive lesions / prostate carcinogenesis / tumor invasion
  •  go-up   go-down


25. Ide S, Sawai T, Kaku N, Nagayoshi Y, Soda H, Kohno S: [Case of pulmonary adenocarcinoma with co-existing pulmonary actinomycosis in one region of the lung]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):823-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A histological examination of the resected tumor showed papillary and acinar adenocarcinoma.
  • [MeSH-major] Actinomycosis / complications. Adenocarcinoma, Papillary / complications. Carcinoma, Acinar Cell / complications. Lung Diseases / complications. Lung Neoplasms / complications
  • [MeSH-minor] Administration, Oral. Amoxicillin / administration & dosage. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Humans. Keratin-19 / blood. Male. Middle Aged. Neoplasms, Multiple Primary. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Anaerobic Actinomyces Infection.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827588.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 804826J2HU / Amoxicillin
  •  go-up   go-down


26. Okudela K, Woo T, Mitsui H, Yazawa T, Shimoyamada H, Tajiri M, Ogawa N, Masuda M, Kitamura H: Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease. Int J Clin Exp Pathol; 2010;3(4):348-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association between postoperative disease recurrence and a variety of morphological features including histological architecture, cell type, cytoplasmic color/internal structure, nuclear shape/size, chromatin pattern, and nucleoli count/remarkableness, was analyzed.
  • Histological architecture had the most prognostic value and could be subdivided into low-grade (bronchioloalveolar, papillary and tubular: "tubular" in this paper is defined as a tubular or glandular structure lined with single-layered neoplastic cells) and high-grade (acinar and solid: "acinar" is defined as a tubular or glandular structure lined with poly-layered neoplastic cells or as a fused glandular structure such as the cribriform pattern) components.
  • The subgroups separated based on a cut-off value, 71.5% of the high-grade component comprised by a tumor, which was calculated according to a relative operating characteristic curve, exhibited a significant difference in disease recurrence [estimated 5-year disease-free survival rate, 95.3% in the low-grade group versus 66.7% in the high-grade group, hazard ratio 7.35, Log-rank test p = 0.002].
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology
  • [MeSH-minor] Disease-Free Survival. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 2010 Feb;34(2):243-55 [20061937.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):341-8 [17350137.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):355-62 [19162366.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 20490327.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2872743
  • [Keywords] NOTNLM ; Lung adenocarcinoma / altered sub-typing system / morphometric profiling / prognostic value / stage I
  •  go-up   go-down


27. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K, Yamada K: Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer; 2010 Sep;69(3):361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer.
  • The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Diagnosis, Differential. Female. Humans. Mutation / genetics. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Time Factors. Tomography, X-Ray Computed. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20659620.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EML4-ALK fusion protein, human; 0 / KRAS protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


28. Zhang R, Humphreys I, Sahu RP, Shi Y, Srivastava SK: In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis; 2008 Dec;13(12):1465-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of AsPC-1 and BxPC-3 cells with capsaicin resulted in a dose-dependent inhibition of cell-viability and induction of apoptosis which was associated with the generation of ROS and persistent disruption of mitochondrial membrane potential.
  • On the contrary, above-mentioned effects were not observed in the normal acinar cells in response to capsaicin-treatment.
  • Furthermore, capsaicin when given orally markedly suppressed the growth of AsPC-1 pancreatic tumor xenografts in athymic nude mice, without side effects.
  • [MeSH-major] Apoptosis / drug effects. Capsaicin / pharmacology. Mitochondria / drug effects. Pancreatic Neoplasms / metabolism. Reactive Oxygen Species / metabolism. Sensory System Agents / pharmacology
  • [MeSH-minor] Animals. Anthracenes / metabolism. Cell Line, Tumor / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Enzyme Activation. Female. Humans. JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors. JNK Mitogen-Activated Protein Kinases / metabolism. Membrane Potential, Mitochondrial / drug effects. Membrane Potential, Mitochondrial / physiology. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPSAICIN .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002586.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129038; United States / NCI NIH HHS / CA / R01 CA106953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Reactive Oxygen Species; 0 / Sensory System Agents; 1TW30Y2766 / pyrazolanthrone; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; S07O44R1ZM / Capsaicin
  •  go-up   go-down


29. Kayed H, Bekasi S, Keleg S, Michalski CW, Giese T, Friess H, Kleeff J: BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Mol Cancer; 2007;6:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we analyzed the expression and role of BGLAP in the normal human pancreas, chronic pancreatitis (CP), and pancreatic ductal adenocarcinoma (PDAC) using quantitative RT-PCR, immunohistochemistry, immunocytochemistry and enzyme immunoassays, as well as cell proliferation and invasion assays.
  • BGLAP was faintly present in the cytoplasm of normal acinar cells but was strongly expressed in the cytoplasm and nuclei of tubular complexes and PanIN lesions of CP and PDAC tissues.
  • Furthermore, BGLAP expression was found in the cancer cells in PDAC tissues as well as in 4 cultured pancreatic cancer cell lines.
  • TNFalpha reduced BGLAP mRNA and protein expression levels in pancreatic cancer cell lines.
  • In addition, BGLAP silencing led to reduction of both cell growth and invasion in those cells.
  • CONCLUSION: BGLAP is expressed in pancreatic cancer cells, where it potentially increases pancreatic cancer cell growth and invasion through autocrine and/or paracrine mechanisms.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Pancreatic Ductal / genetics. Cell Proliferation. Gene Expression Regulation, Neoplastic / physiology. Osteocalcin / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Collagen / metabolism. Drug Combinations. Enzyme-Linked Immunosorbent Assay. Gene Silencing. Humans. Immunoenzyme Techniques. Laminin / metabolism. Middle Aged. Neoplasm Invasiveness. Pancreas / metabolism. Pancreas / pathology. Pancreatitis, Chronic / genetics. Pancreatitis, Chronic / pathology. Proteoglycans / metabolism. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):742-50 [17943729.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):786-93 [17968170.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Apr;6(2):111-8 [15191688.001]
  • [Cites] Pancreas. 2004 Jul;29(1):45-52 [15211111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 May;73(5):1447-51 [1064018.001]
  • [Cites] J Biol Chem. 1980 Jul 25;255(14):6579-83 [6967067.001]
  • [Cites] Am J Surg. 1982 Aug;144(2):243-9 [7102934.001]
  • [Cites] Dtsch Med Wochenschr. 1985 Sep 20;110(38):1442-6 [3875469.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6109-13 [3875856.001]
  • [Cites] Haemostasis. 1986;16(3-4):258-72 [3530901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4455-9 [2786632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6665-9 [1353882.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2704-7 [8389240.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1846-56 [8253361.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Dec 30;205(3):1815-21 [7529022.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):824-31 [7547227.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):448-52 [8684484.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4614-9 [8840973.001]
  • [Cites] Mol Endocrinol. 1996 Nov;10(11):1444-56 [8923469.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):104-8 [9111591.001]
  • [Cites] Cell. 1997 May 30;89(5):747-54 [9182762.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Int J Pancreatol. 1997 Apr;21(2):119-26 [9209953.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1677-83 [9563482.001]
  • [Cites] Bone. 1998 Sep;23(3):187-96 [9737340.001]
  • [Cites] Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80 [9824046.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4554-9 [9845520.001]
  • [Cites] Gastroenterology. 1999 May;116(5):1202-16 [10220513.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):246-61 [10344214.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):224-34 [16041213.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Pol Merkur Lekarski. 2005 Jul;19(109):94-7 [16194038.001]
  • [Cites] Int J Biol Markers. 2005 Jul-Sep;20(3):146-55 [16240842.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53 [17562244.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):21-32 [17290391.001]
  • [Cites] Cancer Treat Rev. 2006;32 Suppl 1:15-9 [16680833.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1106-15 [17876328.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2891-905 [11283267.001]
  • (PMID = 18163903.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 104982-03-8 / Osteocalcin; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2245975
  •  go-up   go-down


30. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE: Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett; 2006 Apr 08;235(1):84-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABCG2 positivity was consistently found in alveolar pneumocytes, sebaceous glands, transitional epithelium of bladder, interstitial cells of testes, prostate epithelium, endocervical cells of uterus, squamous epithelium of cervix, small and large intestinal mucosa/epithelial cells, islet and acinar cells of pancreas, zona reticularis layer of adrenal gland, kidney cortical tubules and hepatocytes.
  • However, many of the cell types expressing ABCG2 have a significant secretory function.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Drug Resistance, Multiple. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990223.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


31. Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F: Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer; 2006 Jul 15;119(2):441-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
  • Understanding the role of signal transduction in regulating pathways responsible for cell growth, survival and apoptosis is critical for cancer therapy.
  • We developed and characterized a HER2/neu and Fas overexpressing cell line (BNT.888 ACA2) from a salivary gland adenocarcinoma that arose in a HER2/neu transgenic mouse.
  • We evaluated the effects of Iressa on signal transduction networks downstream of the activated HER2 and the impact on proliferation, cell cycle and apoptosis.
  • [MeSH-major] Antigens, CD95 / metabolism. Antineoplastic Agents / pharmacology. Carcinoma, Acinar Cell / drug therapy. Neoplasm Proteins / drug effects. Quinazolines / pharmacology. Receptor, ErbB-2 / metabolism. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Caspases / drug effects. Caspases / metabolism. Cell Cycle / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Mice, Transgenic. Mitogen-Activated Protein Kinase Kinases / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Poly(ADP-ribose) Polymerases / drug effects. Poly(ADP-ribose) Polymerases / metabolism. Signal Transduction / drug effects. Up-Regulation


32. Delides A, Velegrakis G, Kontogeorgos G, Karagianni E, Nakas D, Helidonis E: Familial bilateral acinic cell carcinoma of the parotid synchronous with pituitary adenoma: case report. Head Neck; 2005 Sep;27(9):825-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial bilateral acinic cell carcinoma of the parotid synchronous with pituitary adenoma: case report.
  • BACKGROUND: Acinic cell carcinoma is a common neoplasm of the salivary glands that occurs predominately in the parotid.
  • Only one case of a familial recurrence of such a neoplasm and 16 cases of bilateral tumors have been reported.
  • METHODS: History files and histologic reports of a patient with bilateral multifocal acinic cell carcinoma of the parotid and a synchronous pituitary adenoma, and of the patient's sister and his father, also treated for parotid tumours, were retrieved.
  • RESULTS: There was one recurrence of acinic cell carcinoma in the family.
  • A pituitary tumor was a chromophobe gonotrophic adenoma.
  • CONCLUSIONS: This is the 17th case of bilateral acinic cell carcinoma of the parotid gland and the second reported case with a familial recurrence.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Parotid Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15920750.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Shigeishi H, Yoneda S, Taki M, Nobumori T, Ohta K, Higashikawa K, Yasui W, Kamata N: Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors. Oncol Rep; 2006 Apr;15(4):933-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors.
  • Human Bub1 plays an important role at the spindle assembly check-point to prevent cell cycle progression following spindle damage.
  • We examined the expression of Bub1 mRNA and protein in 21 human salivary gland tumors (7 pleomorphic adenomas, 2 warthin tumors, 5 mucoepidermoid carcinomas, 3 adenoid cystic carcinomas and 4 acinic cell carcinomas) and 3 normal submandibular glands using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) or western blotting.
  • We analyzed its relation with the proliferative activity monitored by the Ki-67 labeling index by immunohistochemistry as well as the expression of proliferating cell nuclear antigen (PCNA) by Western blotting.
  • These results indicate that increased expression of the human Bub1 gene is closely linked to abnormal cell proliferation in malignant conditions.
  • [MeSH-major] Cell Proliferation. Protein Kinases / genetics. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / genetics. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Pleomorphic / genetics. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Blotting, Western. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Neoplasm Staging. Proliferating Cell Nuclear Antigen / analysis. Protein-Serine-Threonine Kinases. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525682.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


34. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, Lisanti MP: Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol; 2006 Jan;168(1):292-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness.
  • During breast cancer development, the luminal space of the mammary acinar unit fills with proliferating epithelial cells that exhibit growth factor-independence, cell attachment defects, and a more invasive fibroblastic phenotype.
  • Here, we used primary cultures of mammary epithelial cells derived from genetically engineered mice to identify caveolin-1 (Cav-1) as a critical factor for maintaining the normal architecture of the mammary acinar unit.
  • However, those from Cav-1 (-/-) mice exhibited defects in three-dimensional acinar architecture, including disrupted lumen formation and epidermal growth factor-independent growth due to hyperactivation of the p42/44 mitogen-activated protein kinase cascade.
  • Primary cultures of Cav-1-deficient mammary epithelia will provide a valuable new model to study the spatial/temporal progression of mammary cell transformation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5870-8 [11059785.001]
  • [Cites] Biochemistry. 2000 Nov 14;39(45):13916-24 [11076533.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36803-10 [10969078.001]
  • [Cites] Mol Biol Cell. 2001 Jan;12(1):27-36 [11160820.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6727-38 [11102446.001]
  • [Cites] Biochemistry. 2001 Mar 20;40(11):3354-62 [11258956.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2361-4 [11289096.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6686-91 [11390996.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):534-40 [11544020.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3808-13 [8706028.001]
  • [Cites] Nature. 1996 Sep 12;383(6596):168-72 [8774881.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29182-90 [8910575.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1215-24 [8980228.001]
  • [Cites] Chem Biol. 1996 Nov;3(11):895-904 [8939708.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6525-33 [9045678.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1478-83 [9119990.001]
  • [Cites] Genes Chromosomes Cancer. 1997 May;19(1):1-5 [9135988.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16374-81 [9195944.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18522-5 [9228013.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5353-62 [9311995.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30429-38 [9374534.001]
  • [Cites] Oncogene. 1997 Nov 27;15(22):2727-33 [9400999.001]
  • [Cites] Development. 1998 Jan;125(1):95-105 [9389667.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):759-66 [9485032.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):152-9 [9491327.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5419-22 [9488658.001]
  • [Cites] Oncogene. 1998 Mar;16(11):1391-7 [9525738.001]
  • [Cites] FEBS Lett. 1998 May 29;428(3):205-11 [9654135.001]
  • [Cites] Science. 2001 Sep 28;293(5539):2449-52 [11498544.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):38121-38 [11457855.001]
  • [Cites] Development. 2001 Aug;128(16):3117-31 [11688561.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1553-61 [11733547.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56 [11897507.001]
  • [Cites] Oncogene. 2002 Apr 4;21(15):2365-75 [11948420.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3749-59 [12110587.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):415-32 [12882526.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1187-96 [14961075.001]
  • [Cites] EMBO J. 2004 Mar 10;23(5):1155-65 [14976548.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24745-56 [15044451.001]
  • [Cites] Physiol Rev. 2004 Oct;84(4):1341-79 [15383654.001]
  • [Cites] Oncogene. 2004 Oct 14;23(47):7893-7 [15334058.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Science. 1987 Jul 10;237(4811):178-82 [2885917.001]
  • [Cites] Annu Rev Biochem. 1988;57:443-78 [3052279.001]
  • [Cites] Development. 1989 Feb;105(2):223-35 [2806122.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6370-3 [7987830.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12155-8 [7991599.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36 [7806579.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1381-5 [7877987.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1347-50 [7882334.001]
  • [Cites] EMBO J. 1995 Mar 1;14(5):908-17 [7534227.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15693-701 [7797570.001]
  • [Cites] Oncogene. 1995 Jul 20;11(2):359-63 [7624150.001]
  • [Cites] J Biol Chem. 1996 May 17;271(20):11930-5 [8662667.001]
  • [Cites] Acta Anat (Basel). 1995;154(1):8-20 [8714286.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20448-55 [9685399.001]
  • [Cites] Curr Biol. 1998 Nov 19;8(23):1243-52 [9822576.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6633-48 [9822607.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):580-6 [10049753.001]
  • [Cites] Carcinogenesis. 1999 May;20(5):749-55 [10334190.001]
  • [Cites] Carcinogenesis. 1999 Jul;20(7):1201-8 [10383890.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):31-42 [10505544.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7289-304 [10523618.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51630-46 [15355971.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):431-67 [12223531.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1357-69 [12368209.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Feb;284(2):C457-74 [12388077.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):1027-42 [12631721.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Nat Cell Biol. 1999 Jun;1(2):127-9 [10559886.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4557-68 [10574705.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1507-14 [10669728.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20717-25 [10748172.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):51-62 [10989985.001]
  • [Cites] Oncogene. 2000 Sep 28;19(41):4754-63 [11032026.001]
  • (PMID = 16400031.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007513; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NIDDK NIH HHS / DK / T32-DK07513; United States / NIGMS NIH HHS / GM / T32-GM07288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / Growth Substances; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC1592656
  •  go-up   go-down


35. Kinkor Z, Skálová A: [Acinic cell-like differentiation in invasive ductal carcinoma and in ductal hyperplasia of the breast--report of two cases]. Cesk Patol; 2005 Jan;41(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell-like differentiation in invasive ductal carcinoma and in ductal hyperplasia of the breast--report of two cases].
  • [Transliterated title] "Acinic cell-like" diferenciace v invazivním duktálním karcinomu a duktální hyperlazii mlécné zlázy--popis dvou prípadů.
  • Described are two epithelial lesions of the breast displaying extremely rare, widespread acinic cell-like differentiation (metaplasia).
  • Two women, 70 and 40-year-old, one with invasive ductal papillocarcinoma, the other one with conventional intraductal hyperplasia without atypia, both demonstrated massive diffuse, PAS positive, granular eosinophilic transformation of the cell cytoplasm.
  • This unusual cell appearance closely simulated acinar cells in normal serous salivary gland/acinic cell carcinoma or Paneth cells.
  • Both extensive expression of lysozyme and finding of numerous zymogen granules ultrastructurally confirmed the acinic cell-like fenotype.
  • Discussed is differential diagnosis of the breast neoplasm containing overt eosinophilic and granular cytoplasm.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Ductal, Breast / pathology


36. Tarasova MV, Pozharisskiĭ KM, Ten VP, Arzumanov AA, Kudaĭbergenova AG: [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma]. Arkh Patol; 2009 Nov-Dec;71(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma].
  • The authors have made an immunohistochemical determination of Ki-67, topoisomerase IIalpha, cyclins D1, A, and B1, and calculated their indices in 145 acinar adenocarcinomas of the prostate.
  • This tumor is characterized by a wide range of Ki-67 index (from 3 to 90% or more) although 90% of cases are in the range of 5-35%.
  • The exception is cyclin D1 that shows high expression in intact and tumor tissues, which is frequently greater than that of Ki-67, and its stable expression independent of the Gleason score.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131501.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


37. Bhatia P, Srinivasan R, Rajwanshi A, Nijhawan R, Khandelwal N, Wig J, Vasishtha RK: 5-year review and reappraisal of ultrasound-guided percutaneous transabdominal fine needle aspiration of pancreatic lesions. Acta Cytol; 2008 Sep-Oct;52(5):523-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 142 malignant aspirates, the cytodiagnosis was adenocarcinoma in 126, neuroendocrine/carcinoid tumor in 7, papillary solid epithelial neoplasm in 2, mucinous cystadenocarcinoma in 2, acinar cell carcinoma in 1 and metastatic small cell carcinoma in lung in 4 cases.
  • [MeSH-major] Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2008 Sep-Oct;52(5):521-2 [18833811.001]
  • (PMID = 18833812.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Wang Y, Xie SL, Wang CF, Liu SM, Shan Y, Zhao DB, Liu Q, Luo W, Zhao P: [Clinical and pathological analysis of 114 cases with non-ductal pancreatic adenocarcinoma occupying lesions]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (4) pancreaticoduodenectomy was performed in 26 patients, distal pancreatectomy in 53, tumor enucleation in 15, segmental pancreatectomy in 9, partial resection in 3, duodenum-preserving pancreatic head resection in 1 and palliative surgery (either cholecystojejunostomy anastomosis or gastrojejunostomy) in 7;.
  • (5) pathologic analysis revealed 35 solid pseudopapillary neoplasm of pancreas, 28 pancreatic endocrine tumors, 18 focal chronic pancreatitis, 11 serous cystic neoplasms, 9 mucinous cystic neoplasms, 4 pancreatic cysts, 3 acinar cell carcinomas, 2 pancreatic cavernous hemangiomas, 1 sarcoma of pancreas, 1 sarcomatoid carcinoma of pancreas, 1 pancreatic schwannoma and 1 pancreatic neuroblastoma.
  • CONCLUSION: The non-ductal pancreatic adenocarcinoma-occupying lesions have no specific clinical presentation or serum tumor marker.
  • [MeSH-major] Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. CA-19-9 Antigen / metabolism. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646423.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


39. Maiorano E, Favia G, Pece S, Resta L, Maisonneuve P, Di Fiore PP, Capodiferro S, Urbani U, Viale G: Prognostic implications of NUMB immunoreactivity in salivary gland carcinomas. Int J Immunopathol Pharmacol; 2007 Oct-Dec;20(4):779-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene numb encodes for a protein (Numb) involved in cell fate decisions in Drosophila, with proposed endocytic and developmental functions in mammalians.
  • We set out to explore the immunohistochemical expression of Numb in normal and neoplastic (28 adenoid cystic and 34 mucoepidermoid carcinomas) salivary glands, and correlated the results with the clinico-pathologic features of the neoplasms.
  • Intense Numb immunoreactivity was detected in normal ductal cells and in a subset of acinar cells.
  • In addition, while tumor grade, stage, Ki-67 and Numb immunoreactivity were associated with disease-free survival in univariate analysis, only Numb and Ki-67 immunoreactivities retained independent prognostic significance in multivariate analysis.
  • These data suggest that loss of Numb is implicated in aberrant differentiation programs of salivary gland carcinomas and may serve as a prognostic indicator in patients treated for these neoplasms.
  • [MeSH-major] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / genetics. Membrane Proteins / genetics. Nerve Tissue Proteins / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Ki-67 Antigen / genetics. Male. Middle Aged. Parotid Gland / metabolism. Prognosis. Proportional Hazards Models. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Submandibular Gland / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179751.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Numb protein, human; 0 / RNA, Neoplasm
  •  go-up   go-down


40. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The limited information on spread of tumors of the gallbladder and extrahepatic bile ducts is then reviewed before more detailed consideration of hepatic neoplasms, prompted by recent contributions on hepatocellular carcinoma and intrahepatic cholangiocarcinoma, the latter based on significant experience with this problem in Thailand.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The section on metastatic sarcomas discusses endometrial stromal sarcomas, gastrointestinal stromal neoplasms, and miscellaneous other sarcomas.
  • The endometrial stromal tumors are problematic largely because the history of a primary tumor may be remote, in the ovaries the typical growth and vascular pattern of endometrial stromal neoplasms is not always conspicuous, and some endometrial stromal sarcomas in the ovary show sex cordlike patterns of growth.
  • Recent information has indicated that gastrointestinal stromal tumors may rarely have significant ovarian manifestations and if the primary neoplasm is overlooked, the ovarian tumor may be misdiagnosed, usually as an ovarian fibromatous tumor, but potentially as another primary neoplasm.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The final neoplasms considered are malignant mesothelioma and the desmoplastic small round cell tumor.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • Nonetheless, differences exist in most cases and awareness of the entity should lead to consideration of the desmoplastic neoplasm, particularly in a young female.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


41. Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Ghossein RA, Lee NY: Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer; 2009 May 15;115(10):2128-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.
  • BACKGROUND: To the authors' knowledge, the indications for adjuvant treatment in acinic cell carcinoma (AciCC) of the parotid gland have not been elucidated to date.
  • If high-grade tumors were defined on the basis of high mitotic activity (>2 mitoses/10 HPF) and/or tumor necrosis, high-grade carcinomas had a significantly lower DFS and OS (P = .001).
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Facial Nerve Injuries / etiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309749.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kaba S, Kojima M, Matsuda H, Sugihara S, Masawa N, Kobayashi TK, Fukuda T: Küttner's tumor of the submandibular glands: report of five cases with fine-needle aspiration cytology. Diagn Cytopathol; 2006 Sep;34(9):631-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Küttner's tumor of the submandibular glands: report of five cases with fine-needle aspiration cytology.
  • Küttner's tumor (KT) is a benign tumor-like lesion of the salivary gland that mimics neoplasm clinically because of presentation as a hard mass.
  • Smears obtained from two cases contained moderate to large numbers of lymphoid cells without definite cytological atypia, scattered ductal structures, and acinar cell clusters.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Lymphoma / pathology. Male. Middle Aged. Retrospective Studies. Salivary Ducts / pathology. Salivary Gland Neoplasms / pathology. Sclerosis / pathology. Sclerosis / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16900478.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Anderson LR, Sutherland RL, Butt AJ: BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation. Oncogene; 2010 Jan 28;29(4):527-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When cultured in 3D, MCF-10A cells undergo a highly regulated morphogenic program leading to the development of polarized acinar structures containing a central, hollow lumen formed, in part, through the induction of BIM-dependent apoptosis.
  • [MeSH-major] Apoptosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-raf / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Butadienes / pharmacology. Cell Culture Techniques. Cell Line. Cell Line, Tumor. Enzyme Activation. Humans. MAP Kinase Signaling System / drug effects. Mammary Glands, Human / cytology. Mammary Glands, Human / metabolism. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 3 / metabolism. Mitogen-Activated Protein Kinase Kinases / metabolism. Neoplasm Invasiveness / genetics. Nitriles / pharmacology. Protein Kinase Inhibitors / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881545.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2-associated athanogene 1 protein; 0 / Butadienes; 0 / DNA-Binding Proteins; 0 / Nitriles; 0 / Protein Kinase Inhibitors; 0 / Transcription Factors; 0 / U 0126; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


44. Hartzell HC, Yu K, Xiao Q, Chien LT, Qu Z: Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels. J Physiol; 2009 May 15;587(Pt 10):2127-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ca(2+)-activated Cl- channels (CaCCs) perform many important functions in cell physiology including secretion of fluids from acinar cells of secretory glands, amplification of olfactory transduction, regulation of cardiac and neuronal excitability, mediation of the fast block to polyspermy in amphibian oocytes, and regulation of vascular tone.

  • Genetics Home Reference. consumer health - ANO5 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1986 Aug 1;233(4763):558-60 [2425436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5063-7 [2440042.001]
  • [Cites] Pflugers Arch. 1988 Oct;412(6):641-6 [2850536.001]
  • [Cites] J Gen Physiol. 1990 May;95(5):773-89 [2163430.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Neuron. 1991 Apr;6(4):547-55 [1849722.001]
  • [Cites] J Neurophysiol. 1992 Dec;68(6):2042-50 [1283407.001]
  • [Cites] Am J Physiol. 1993 Apr;264(4 Pt 1):C977-85 [7682780.001]
  • [Cites] Pflugers Arch. 1993 Aug;424(3-4):231-7 [8414911.001]
  • [Cites] J Gen Physiol. 1994 Aug;104(2):357-73 [7807053.001]
  • [Cites] Yeast. 1994 Oct;10(10):1363-81 [7900426.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31016-26 [8537359.001]
  • [Cites] J Physiol. 1995 Nov 1;488 ( Pt 3):689-99 [8576858.001]
  • [Cites] Circ Res. 1996 May;78(5):936-44 [8620614.001]
  • [Cites] Am J Physiol. 1996 Aug;271(2 Pt 1):G304-10 [8770046.001]
  • [Cites] J Gen Physiol. 1996 Jul;108(1):35-47 [8817383.001]
  • [Cites] J Physiol. 1997 Jan 15;498 ( Pt 2):381-96 [9032686.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):C161-6 [9458724.001]
  • [Cites] Prog Biophys Mol Biol. 1997;68(1):69-119 [9481145.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 1):C161-75 [9886932.001]
  • [Cites] Int J Mol Med. 2005 Feb;15(2):353-8 [15647853.001]
  • [Cites] J Physiol. 2005 Jan 15;562(Pt 2):477-91 [15564283.001]
  • [Cites] J Biol Chem. 2009 Oct 23;284(43):29405-12 [17003041.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 1):E969-76 [7491950.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):H1732-44 [10564126.001]
  • [Cites] J Gen Physiol. 2000 Jan;115(1):59-80 [10613919.001]
  • [Cites] Mol Gen Genet. 1999 Dec;262(4-5):683-702 [10628851.001]
  • [Cites] Science. 2000 Oct 13;290(5490):341-4 [11030653.001]
  • [Cites] Pflugers Arch. 2001 May;442(2):273-9 [11417225.001]
  • [Cites] Eukaryot Cell. 2002 Aug;1(4):606-12 [12456008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903 [12477932.001]
  • [Cites] J Physiol. 2003 Feb 15;547(Pt 1):181-96 [12562904.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 14;302(3):534-8 [12615067.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):174-6 [12734416.001]
  • [Cites] Prostate. 2005 Sep 1;64(4):387-400 [15761874.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(1):22-7 [16113407.001]
  • [Cites] Int J Mol Med. 2005 Nov;16(5):919-24 [16211264.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):141-7 [16219661.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1821-31 [16261155.001]
  • [Cites] J Gen Physiol. 2006 May;127(5):577-89 [16636205.001]
  • [Cites] J Gen Physiol. 2006 Jul;128(1):73-87 [16801382.001]
  • [Cites] J Gen Physiol. 2006 Sep;128(3):247-59 [16940553.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1058-69 [16906560.001]
  • [Cites] J Cell Physiol. 2007 Mar;210(3):831-42 [17111356.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1594-601 [17308099.001]
  • [Cites] Biochem Biophys Res Commun. 2007 May 25;357(1):126-32 [17418107.001]
  • [Cites] J Neurophysiol. 2007 Jul;98(1):86-95 [17460105.001]
  • [Cites] Eukaryot Cell. 2005 Feb;4(2):281-8 [15701790.001]
  • [Cites] Annu Rev Physiol. 2005;67:719-58 [15709976.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1099-106 [15882990.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):613-22 [15911878.001]
  • [Cites] Physiol Rev. 2005 Jul;85(3):1061-92 [15987802.001]
  • [Cites] Physiol Rev. 2008 Apr;88(2):639-72 [18391176.001]
  • [Cites] Curr Opin Neurobiol. 2008 Feb;18(1):60-8 [18508259.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Jul;233(7):779-91 [18445774.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H97-H104 [18441200.001]
  • [Cites] J Gastroenterol. 2008;43(7):531-7 [18648740.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6306-12 [18676855.001]
  • [Cites] Dev Biol. 2008 Sep 1;321(1):141-9 [18585372.001]
  • [Cites] Dev Dyn. 2008 Sep;237(9):2566-74 [18729231.001]
  • [Cites] Channels (Austin). 2008 Jul-Aug;2(4):252-60 [18769137.001]
  • [Cites] Cell. 2008 Sep 19;134(6):1019-29 [18805094.001]
  • [Cites] Circ Res. 2008 Oct 10;103(8):864-72 [18776041.001]
  • [Cites] Science. 2008 Oct 24;322(5901):590-4 [18772398.001]
  • [Cites] Nature. 2008 Oct 30;455(7217):1210-5 [18724360.001]
  • [Cites] J Cell Biol. 2002 Jan 7;156(1):75-85 [11781335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4008-13 [11904445.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):503-68 [11917096.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11369-74 [12172009.001]
  • [Cites] Pflugers Arch. 2007 Sep;454(6):879-89 [17361457.001]
  • [Cites] J Gen Physiol. 2007 Nov;130(5):513-24 [17968025.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):210-8 [18223323.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):758-68 [18083779.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1611-3 [18339837.001]
  • [Cites] J Mol Evol. 1995 Nov;41(5):675-9 [18345592.001]
  • [Cites] Anticancer Res. 2008 Jan-Feb;28(1A):75-83 [18383827.001]
  • [Cites] Int J Oncol. 2003 Jun;22(6):1375-81 [12739008.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Aug;285(2):F326-35 [12724129.001]
  • [Cites] Curr Opin Neurobiol. 2003 Aug;13(4):469-75 [12965295.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41114-25 [12907679.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49563-72 [12939260.001]
  • [Cites] J Neurophysiol. 2003 Dec;90(6):3764-73 [12944538.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3059-64 [14981236.001]
  • [Cites] Mol Biol Evol. 2004 Mar;21(3):587-98 [14694080.001]
  • [Cites] Curr Biol. 2004 Mar 9;14(5):406-11 [15028216.001]
  • [Cites] J Gen Physiol. 2004 Apr;123(4):323-5 [15051804.001]
  • [Cites] J Gen Physiol. 2004 Apr;123(4):327-40 [15051805.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1255-61 [15124103.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22461-8 [15010458.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):107-13 [15215166.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1982 Jul 22;215(1201):491-7 [6127718.001]
  • [Cites] J Physiol. 1982 Oct;331:253-84 [7153904.001]
  • [Cites] J Physiol. 1983 Sep;342:309-25 [6313909.001]
  • (PMID = 19015192.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060448-08; United States / NIGMS NIH HHS / GM / GM060448-08; United States / NEI NIH HHS / EY / EY014852-08; United States / NEI NIH HHS / EY / R01 EY014852-08; United States / NIGMS NIH HHS / GM / R01 GM060448; United States / NEI NIH HHS / EY / R01 EY014852; United States / NIGMS NIH HHS / GM / GM60448; United States / NEI NIH HHS / EY / EY014852
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ANO1 protein, human; 0 / Chloride Channels; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC2697287
  •  go-up   go-down


45. Yamaguchi E, Nakayama T, Nanashima A, Matsumoto K, Yasutake T, Sekine I, Nagayasu T: Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med; 2007 Sep;213(1):41-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesized that Ets-1 expression is also associated with tumor progression and a worse prognosis in lung carcinoma patients.
  • To clarify the role of the Ets-1 proto-oncogene, the expression of Ets-1 in non-small cell lung carcinomas using 156 paraffin-embedded specimens was determined in surgically resected tissue samples.
  • Immunohistochemical staining showed Ets-1 expression in 82 cases of 156 carcinomas (53%): 36 of 52 (69%) squamous cell carcinomas, 41 of 96 (43%) adenocarcinomas, and 5 of 8 (63%) other carcinomas.
  • In adenocarcinomas, a higher proportion of acinar type expressed Ets-1 compared to papillary or alveolar type (p < 0.05).
  • Such relationship was not observed among squamous cell carcinoma patients.
  • Our findings indicate that Ets-1 expression is related to histopathological differentiation, morphogenesis, and tumor progression of lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Proto-Oncogene Protein c-ets-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Analysis. Survivors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785952.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1
  •  go-up   go-down


46. Hu YH, Tuo XP, Jin ZD, Liu Y, Guo Y, Luo L: Endoscopic ultrasound (EUS)-guided ethanol injection in hepatic metastatic carcinoma: a case report. Endoscopy; 2010;42 Suppl 2:E256-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Endosonography. Ethanol / administration & dosage. Injections, Intra-Arterial / methods. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. Iodine Radioisotopes / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / physiopathology. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931470.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 3K9958V90M / Ethanol
  •  go-up   go-down


47. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The authors describe a clinical case of neck tumour with initially unclear etiology.
  • The preoperative diagnostics including ultrasonography, thin-needle puncture, MRI, carotid angiography and videostroboscopy was significant for surgical treatment planning; yet it was the intraoperative clinical picture which indicated that the tumour derived from the inferior parotid pole.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • Two and a half years after the procedure, the patient presented with a tumour localized on the front thoracic wall and two rapidly enlarging tumours in the nape of the neck.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


48. Reske SN: [PET and PET-CT of malignant tumors of the exocrine pancreas]. Radiologe; 2009 Feb;49(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoma, Acinar Cell / diagnostic imaging. Carcinoma, Pancreatic Ductal / diagnostic imaging. Image Processing, Computer-Assisted. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / diagnostic imaging. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Staging. Pancreas / diagnostic imaging. Pancreas / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1437-44 [18703612.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Eur J Nucl Med. 1998 Mar;25(3):259-64 [9580859.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):250-5 [10025831.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1352 [15197505.001]
  • [Cites] J Gastroenterol. 2003;38(12 ):1189-93 [14714260.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404 [15549297.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):475-6 [16012303.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Oct;26(10 ):888-92 [12434099.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85 [18481063.001]
  • [Cites] Recent Results Cancer Res. 2008;177:15-26 [18084943.001]
  • [Cites] Nuklearmedizin. 2005;44 Suppl 1:S18-23 [16395974.001]
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):197-201 [11852308.001]
  • [Cites] Scand J Surg. 2004;93(3):191-7 [15544073.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):131-136 [14516536.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1408-13 [18703604.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10 (10 ):1354-60 [17175454.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):50-5 [14767734.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):287-93 [10917540.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Ann Nucl Med. 2001 Jun;15(3):217-24 [11545191.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Pancreas. 2000 Mar;20(2):109-16 [10707924.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Pancreatology. 2005;5(6):553-61 [16113592.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):239-46 [15972430.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):480-508 [18287273.001]
  • [Cites] Pancreatology. 2005;5(2-3):266-72 [15855825.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19219476.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 43
  •  go-up   go-down


49. Kawakami H, Kuwatani M, Onodera M, Hirano S, Kondo S, Nakanishi Y, Itoh T, Asaka M: Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol; 2007 Aug;42(8):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the ampulla of Vater.
  • Acinar cell carcinoma of the pancreatobiliary system is a relatively rare malignant neoplasm arising usually in the pancreatic parenchyma.
  • The patient underwent a curative surgical operation, and histopathological examination revealed that the tumor was confined to the ampulla of Vater with no continuity to the pancreatic parenchyma.
  • The tumor cells showed acinar or tubular arrangement with eosinophilic to basophilic granular cytoplasm, findings identical to those of acinar cell carcinoma of the pancreas.
  • Immunohistochemically, the tumor cells were positive for lipase.
  • From these findings, we concluded that the tumor was primary acinar cell carcinoma arising in the ampulla of Vater, probably originating from heterotopic pancreatic tissue.
  • This is the first reported case of primary acinar cell carcinoma in the ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma, Acinar Cell / diagnosis. Common Bile Duct Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Dig Surg. 2005;22(5):377-9 [16432300.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):568-71 [8192567.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):121-3 [11154509.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):101-7 [9020300.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 17701134.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Triantafillidou K, Iordanidis F, Psomaderis K, Kalimeras E: Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study. J Oral Maxillofac Surg; 2010 Oct;68(10):2489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.
  • PURPOSE: Acinic cell carcinoma is a rare malignant tumor of salivary glands.
  • The purpose of this study is to evaluate the clinical outcome of acinic cell carcinoma in a group of 11 patients, who were treated in our clinic, and to discuss the management as well as the immunohistochemical features and prognosis of this carcinoma.
  • MATERIALS AND METHODS: The study included 11 patients with acinic cell carcinoma of the minor salivary glands who were treated in our clinic.
  • CONCLUSIONS: Acinic cell carcinoma is a rare malignant tumor of the salivary glands, characterized by an indolent clinical course with the potential for both local recurrence and distant metastases.
  • The immunohistochemical analysis of proliferation markers provides additional prognostic information for this tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis


51. Tiacci E, Orvietani PL, Bigerna B, Pucciarini A, Corthals GL, Pettirossi V, Martelli MP, Liso A, Benedetti R, Pacini R, Bolli N, Pileri S, Pulford K, Gambacorta M, Carbone A, Pasquarello C, Scherl A, Robertson H, Sciurpi MT, Alunni-Bistocchi G, Binaglia L, Byrne JA, Falini B: Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. Blood; 2005 Apr 1;105(7):2812-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI.
  • Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)/mass-spectrometry analysis identified the 28-kDa protein as human tumor protein D52 (TPD52), whose expression had been previously described only in normal and neoplastic epithelia.
  • In fact, unlike other B-cell molecules (paired box 5 [PAX5], CD19, CD79a, CD20, CD22), which are down-regulated during differentiation from B cells to plasma cells, TPD52 expression reached its maximum levels at the plasma cell stage.
  • In the Thiel myeloma cell line, TPD52 bound to annexin VI in a Ca(2+)-dependent manner, suggesting that these molecules may act in concert to regulate secretory processes in plasma cells, similarly to what was observed in pancreatic acinar cells.
  • Finally, the anti-TPD52 monoclonal antibody served as a valuable tool for the diagnosis of B-cell malignancies.
  • [MeSH-major] Annexin A6 / metabolism. Calcium / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Plasma Cells / physiology
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibody Specificity. B-Lymphocytes / physiology. Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Epitopes, B-Lymphocyte / immunology. Gene Expression Regulation, Leukemic / immunology. Leukemia, B-Cell / diagnosis. Leukemia, B-Cell / physiopathology. Mass Spectrometry. Mice. Mice, Inbred BALB C. Molecular Weight. Receptors, Cell Surface / immunology. Receptors, Fc

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15576473.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A6; 0 / Antibodies, Monoclonal; 0 / Epitopes, B-Lymphocyte; 0 / FCRL4 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, Fc; 0 / TPD52 protein, human; SY7Q814VUP / Calcium
  •  go-up   go-down


52. Wendt MK, Smith JA, Schiemann WP: p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem; 2009 Dec 4;284(49):34145-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.
  • During breast cancer progression, transforming growth factor-beta (TGF-beta) switches from a tumor suppressor to a pro-metastatic molecule.
  • This shift in TGF-beta signaling evoked (i) resistance to TGF-beta-induced growth arrest, and (ii) acinar filling upon three-dimensional organotypic cultures of p130Cas-FL or -CT expressing MECs.
  • Importantly, depleting p130Cas expression in TbetaR-II-expressing metastatic MECs significantly increased their activation of Smad2/3, which (i) reestablished the physiologic balance between canonical and noncanonical TGF-beta signaling, and (ii) reversed cellular invasion and early mammary tumor cell dissemination stimulated by TGF-beta.
  • Collectively, our findings identify p130Cas as a molecular rheostat that regulates the delicate balance between canonical and noncanonical TGF-beta signaling, a balance that is critical to maintaining the tumor suppressor function of TGF-beta during breast cancer progression.


53. Liu T, Zhu E, Wang L, Okada T, Yamaguchi A, Okada N: Abnormal expression of Rb pathway-related proteins in salivary gland acinic cell carcinoma. Hum Pathol; 2005 Sep;36(9):962-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal expression of Rb pathway-related proteins in salivary gland acinic cell carcinoma.
  • Salivary gland acinic cell carcinoma (ACC) is a relatively rare neoplasm, and limited information is available regarding its molecular pathogenesis.
  • The expression of topoisomerase II-alpha and Ki-67 was also examined to evaluate cell proliferation.
  • Double immunofluorescent staining demonstrated that pRb-S795 was colocalized with cyclin D1 in most tumor cells.
  • [MeSH-major] Carcinoma, Acinar Cell / metabolism. Retinoblastoma Protein / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Neoplasm / metabolism. Cyclin D1 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged


54. Vakiani E, Young RH, Carcangiu ML, Klimstra DS: Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases. Am J Surg Pathol; 2008 Oct;32(10):1540-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases.
  • We report 4 cases of acinar cell carcinoma of the pancreas, 3 presenting as metastases in the ovary, the first report of this circumstance, which may pose a broad differential diagnosis and caused significant diagnostic difficulty in all the cases.
  • In 3 cases, the ovarian tumors were detected before the pancreatic tumor; in 1 case, a large abdominal mass and ovarian tumors were discovered synchronously.
  • The ovarian tumors were large, solid, white-tan on gross examination, and bilateral in 3 cases; the single case involving only 1 ovary had 2 discrete masses of tumor.
  • Microscopic examination showed highly cellular neoplasms with a small amount of fibrous stroma.
  • Two cases had a predominant acinar growth pattern of cells with brightly eosinophilic, granular cytoplasm.
  • The main differential diagnostic consideration was well-differentiated neuroendocrine neoplasm (carcinoid tumor); positive immunostaining with antibodies against chymotrypsin and trypsin and negative immunostaining with antibodies against synaptophysin and chromogranin helped exclude this diagnosis.
  • We observed focal alpha-inhibin immunostaining in 2 cases, which may represent a potential diagnostic pitfall, as a Sertoli cell tumor or unusual granulosa cell tumor may also enter the differential diagnosis.
  • Inclusion of antibodies against the pancreatic enzymes chymotrypsin and trypsin in the immunohistochemical panel is critical in establishing the correct diagnosis and should be considered when evaluating ovarian tumors with architectural (mainly acinar) and cytologic (granular eosinophilic cytoplasm) characteristics that should bring a metastatic acinar cell carcinoma into consideration.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Ovarian Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724247.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Hutchinson CB, Canlas K, Evans JA, Obando JV, Waugh M: Endoscopic ultrasound-guided fine needle aspiration biopsy of the intrapancreatic accessory spleen: a report of 2 cases. Acta Cytol; 2010 May-Jun;54(3):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intrapancreatic accessory spleen (IPAS) can pose a challenge in the diagnostic workup by mimicking a pancreatic neoplasm.
  • In both cases, the cytomorphologic appearance of smears and cell blocks demonstrated aggregates of benign splenic tissue characteristic of both white and red pulp.
  • Rare fragments of pancreatic acinar tissue were also identified.
  • One cell block demonstrated benign splenic and pancreatic parenchyma immediately adjacent to one another without an apparent intervening capsule.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Antigens, CD / metabolism. Biomarkers / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endocrine Gland Neoplasms / diagnosis. Endosonography. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518423.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers
  •  go-up   go-down


56. Thomason T, Oxford LE, Ducic Y: Metastatic acinic cell carcinoma presenting as a recurrent pituitary adenoma. J Otolaryngol; 2007 Dec;36(6):E91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinic cell carcinoma presenting as a recurrent pituitary adenoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076836.001).
  • [ISSN] 0707-7270
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


57. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature; 2008 Mar 13;452(7184):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.
  • Mechanisms underlying global changes in gene expression during tumour progression are poorly understood.
  • RNA-interference-mediated knockdown of SATB1 in highly aggressive (MDA-MB-231) cancer cells altered the expression of >1,000 genes, reversing tumorigenesis by restoring breast-like acinar polarity and inhibiting tumour growth and metastasis in vivo.
  • Conversely, ectopic SATB1 expression in non-aggressive (SKBR3) cells led to gene expression patterns consistent with aggressive-tumour phenotypes, acquiring metastatic activity in vivo.
  • SATB1 delineates specific epigenetic modifications at target gene loci, directly upregulating metastasis-associated genes while downregulating tumour-suppressor genes.
  • SATB1 reprogrammes chromatin organization and the transcription profiles of breast tumours to promote growth and metastasis; this is a new mechanism of tumour progression.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic / genetics. Matrix Attachment Region Binding Proteins / metabolism. Neoplasm Metastasis / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Line. Cell Line, Tumor. Cell Polarity. Disease Progression. Epigenesis, Genetic / genetics. Gene Expression Profiling. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secretion. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Mice. Mice, Nude. Neoplasm Transplantation. Phenotype. Prognosis. RNA Interference


58. Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, Bergmann F, Schmidt J, Werner J, Buchler MW, Jaeger D, Giese NA: Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother; 2010 Sep;59(9):1389-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to comprehend the spectrum of pancreatic tumor-associated antigens (pTAAs) and to assess the clinical relevance of their immunogenicity.
  • QRT-PCR and immunohistochemistry characterized PNLIPRP2 as a robust acinar cell-specific marker whose decreased expression mirrored the disappearance of parenchyma in the diseased organ, but was not related to the presence of PNLIPRP2 autoantibodies.
  • The observed pTAA spectrum comprised molecules associated with acinar, stromal and malignant structures, thus presenting novel targets for tumor cell-specific therapies as well as for approaches based on the bystander effects.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / immunology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / immunology
  • [MeSH-minor] Aged. Antigens, Tumor-Associated, Carbohydrate / genetics. Antigens, Tumor-Associated, Carbohydrate / immunology. Antigens, Tumor-Associated, Carbohydrate / metabolism. Autoantibodies / blood. Cloning, Molecular. Enzyme-Linked Immunosorbent Assay. Female. Gene Library. Humans. Immunochemistry. Lipase / genetics. Lipase / immunology. Lipase / metabolism. Male. Middle Aged. Neoplasm Staging. Pancreas / metabolism. Pancreas / pathology. Prognosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514540.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Autoantibodies; 0 / MIA antigen, human; EC 3.1.1.- / pancreatic lipase related protein 2; EC 3.1.1.3 / Lipase
  •  go-up   go-down


59. Viterbo D, Callender GE, DiMaio T, Mueller CM, Smith-Norowitz T, Zenilman ME, Bluth MH: Administration of anti-Reg I and anti-PAPII antibodies worsens pancreatitis. JOP; 2009 Jan 08;10(1):15-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The regeneration protein family (Reg), which includes Reg I and PAPII, is expressed in pancreas acinar cells, and increases in acute pancreatitis.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. TAUROCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2000 Mar;89(1):60-5 [10720454.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8290-5 [10880565.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1948-58 [18641332.001]
  • [Cites] Gut. 2007 Aug;56(8):1091-7 [17409121.001]
  • [Cites] Pancreas. 2007 Jan;34(1):1-14 [17198179.001]
  • [Cites] World J Gastroenterol. 2006 Jul 28;12(28):4511-6 [16874863.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):580-6 [16327837.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Oct;2(10):473-83 [16224479.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):520-5 [15885230.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):254-62 [10526060.001]
  • [Cites] Clin Chim Acta. 1998 May 25;273(2):185-94 [9657348.001]
  • [Cites] Digestion. 1998;59(3):186-91 [9643677.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):150-4 [10662590.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):646-52 [11066135.001]
  • [Cites] J Surg Res. 2002 Jun 15;105(2):136-44 [12121700.001]
  • [Cites] J Investig Med. 2002 Nov;50(6):421-34 [12425429.001]
  • [Cites] Diabetes. 2002 Dec;51 Suppl 3:S478-83 [12475793.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):91-6 [15011837.001]
  • [Cites] Scand J Gastroenterol. 2004 Sep;39(9):870-81 [15513386.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Apr 27;87(4):1176-82 [111670.001]
  • [Cites] Diabetes. 1984 Apr;33(4):401-4 [6323238.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2115-26 [3908481.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):1056-63 [2428840.001]
  • [Cites] J Biol Chem. 1988 Feb 15;263(5):2111-4 [2963000.001]
  • [Cites] Genomics. 1994 Mar 15;20(2):305-7 [8020983.001]
  • [Cites] J Gastroenterol. 1995 Oct;30(5):643-50 [8574338.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):429-33 [8549770.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 5;225(1):16-21 [8769088.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):543-50 [9024308.001]
  • (PMID = 19129610.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK054511-05; United States / NIDDK NIH HHS / DK / R01 DK054511-04; United States / NIDDK NIH HHS / DK / DK054511-04; United States / NIDDK NIH HHS / DK / R01 DK054511-05; United States / NIDDK NIH HHS / DK / R01 DK054511-03S1; United States / NIDDK NIH HHS / DK / Z01 DK054511; United States / NIDDK NIH HHS / DK / DK054511-03S1; United States / NIDDK NIH HHS / DK / R01DK54511
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Reg1 protein, rat; 0 / pancreatitis-associated protein; 5E090O0G3Z / Taurocholic Acid
  • [Other-IDs] NLM/ NIHMS97437; NLM/ PMC2666878
  •  go-up   go-down


60. Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH: A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys; 2010 Jan 1;76(1):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Factors associated with neck nodal involvement on univariate analysis included increasing age, male sex, increasing tumor size, high tumor grade, T3-T4 stage, adenocarcinoma or mucoepidermoid carcinomas, and pharyngeal site of primary malignancy.
  • [MeSH-major] Adenocarcinoma / secondary. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Age Factors. Analysis of Variance. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / secondary. Chi-Square Distribution. Female. Humans. Laryngeal Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms / pathology. Neck. Neck Dissection. Neoplasm Staging. Nose Neoplasms / pathology. Pharyngeal Neoplasms / pathology. Prognosis. SEER Program. Sex Factors. Tumor Burden

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386433.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


61. Lee HJ, Lee YJ, Kwon HC, Bae S, Kim SH, Min JJ, Cho CK, Lee YS: Radioprotective effect of heat shock protein 25 on submandibular glands of rats. Am J Pathol; 2006 Nov;169(5):1601-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced apoptosis, caspase-3 activation, and poly(ADP-ribose) polymerase cleavage in acinar cells, granular convoluted cells, and intercalated ductal cells were also inhibited by HSP25 or HSP70i transfer.
  • [MeSH-major] Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Radiation-Protective Agents / metabolism. Submandibular Gland / metabolism. Submandibular Gland / radiation effects

  • Hazardous Substances Data Bank. PILOCARPINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2002 Apr;9(4):448-56 [11965498.001]
  • [Cites] Radiat Res. 1997 Sep;148(3):240-7 [9291355.001]
  • [Cites] Trends Endocrinol Metab. 2002 Oct;13(8):355-60 [12217493.001]
  • [Cites] Free Radic Biol Med. 2004 Feb 15;36(4):429-44 [14975446.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6660-5 [15374981.001]
  • [Cites] Cancer. 1976 Jul;38(1):273-8 [7352.001]
  • [Cites] Radiat Res. 1978 Aug;75(2):317-26 [213806.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 29;238(3):891-5 [9325187.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):C1549-61 [9374640.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1A):315-20 [9568096.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 28;245(3):835-40 [9588201.001]
  • [Cites] Circ Res. 1998 Jul 27;83(2):117-32 [9686751.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):5061-9 [9988753.001]
  • [Cites] Cell Tissue Res. 1999 Mar;295(3):513-21 [10022971.001]
  • [Cites] Annu Rev Physiol. 1999;61:243-82 [10099689.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20071-4 [10400615.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18108-19 [15731106.001]
  • [Cites] Radiat Res. 2000 Mar;153(3):318-26 [10669554.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(4):443-60 [6145251.001]
  • [Cites] J Histochem Cytochem. 1988 Sep;36(9):1139-45 [2841372.001]
  • [Cites] J Neurochem. 1993 Feb;60(2):659-65 [8380440.001]
  • [Cites] J Cell Physiol. 1992 Jun;151(3):561-70 [1295903.001]
  • [Cites] Neuroscience. 1993 Aug;55(3):621-7 [8413925.001]
  • [Cites] Radiat Res. 1993 Oct;136(1):42-7 [8210337.001]
  • [Cites] J Neurochem. 1994 Nov;63(5):1787-95 [7931334.001]
  • [Cites] Methods Cell Biol. 1994;43 Pt A:161-89 [7823861.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1908-12 [7530250.001]
  • [Cites] Pflugers Arch. 1994 Dec;429(2):240-4 [7892110.001]
  • [Cites] Curr Opin Cell Biol. 1995 Aug;7(4):472-83 [7495566.001]
  • [Cites] Neurosci Lett. 1995 Nov 17;200(2):85-8 [8614569.001]
  • [Cites] Exp Cell Res. 1996 Feb 25;223(1):163-70 [8635489.001]
  • [Cites] Methods Mol Biol. 2000;99:421-9 [10909096.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23413-20 [11290736.001]
  • [Cites] J Virol. 2001 Oct;75(20):9579-84 [11559789.001]
  • [Cites] Radiat Res. 2002 Nov;158(5):641-9 [12385642.001]
  • [Cites] Oncology. 2002;63 Suppl 2:2-10 [12466639.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):247-50 [12578459.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):351-60 [12600238.001]
  • [Cites] Lancet Oncol. 2003 Jun;4(6):378-81 [12788413.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(3):199-212 [12799323.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):593 [14554234.001]
  • [Cites] Neurosci Lett. 1996 Mar 8;206(1):45-8 [8848278.001]
  • [Cites] Oral Dis. 2002 May;8(3):141-6 [12108758.001]
  • (PMID = 17071584.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aquaporin 5; 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Hspb1 protein, mouse; 0 / Neoplasm Proteins; 0 / Radiation-Protective Agents; 01MI4Q9DI3 / Pilocarpine; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC1780208
  •  go-up   go-down


62. Sánchez-Mora N, Rendón-Henao J, Monroy V, Herranz Alandro M, Alvarez-Fernández E: Antigenic profile of human bronchial gland. Histol Histopathol; 2005 07;20(3):865-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acinar united is composed by mucous, serous and mixed units.
  • Additionally, serous acinar cells reacted with AE3, CK19, CK5/6/8/18, CK8/18/19, and Leu7.
  • Ductal system cells differed from acinar secretory cells in expressing CK34betaE12 and HSP27.
  • In conclusion, the detailed knowledge of the immunohistochemical reactivities of normal cell types of normal human bronchial glands will prove useful in studies of bronchial pathology, especially of neoplastic processes.
  • [MeSH-minor] Actins / analysis. Antigens / analysis. Exocrine Glands / chemistry. Exocrine Glands / immunology. HSP27 Heat-Shock Proteins. HSP70 Heat-Shock Proteins / analysis. Heat-Shock Proteins / analysis. Humans. Immunohistochemistry. Intermediate Filaments / metabolism. Keratin-7. Keratins / analysis. Muscle, Smooth / chemistry. Neoplasm Proteins / analysis. Neprilysin / analysis. S100 Proteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944937.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens; 0 / Biomarkers; 0 / HSP27 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Neoplasm Proteins; 0 / S100 Proteins; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


63. Yang TM, Han SC, Wu CJ, Mo LR: Acinar cell carcinomas with exophytic growth and intraductal pancreatic duct invasion: peculiar multislice computed tomographic picture. J Hepatobiliary Pancreat Surg; 2009;16(2):238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinomas with exophytic growth and intraductal pancreatic duct invasion: peculiar multislice computed tomographic picture.
  • MSCT showed 8.4 cm well-enhancing exophytic tumor of the pancreatic head which also protruded into the duodenum.
  • The pathological diagnosis was acinar cell carcinoma (ACC) originating in the pancreatic head and directly invading through the duodenal wall and the main pancreatic duct, without any lymph node involvement.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Invasiveness. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183830.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A: [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer]. Actas Urol Esp; 2008 Jul-Aug;32(7):680-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer].
  • [Transliterated title] Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata.
  • INTRODUCTION: Prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP) in the setting of prostatic needle biopsies are considered premalignant although questions still remain.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Humans. Male. Middle Aged. Retrospective Studies


65. Othman M, Basturk O, Groisman G, Krasinskas A, Adsay NV: Squamoid cyst of pancreatic ducts: A distinct type of cystic lesion in the pancreas. Am J Surg Pathol; 2007 Feb;31(2):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinicopathologic features of a hitherto unrecognized cystic tumor of the pancreas are documented, and its possible relationship to a more common incidental microscopic lesion is analyzed.
  • The cells forming the basal/parabasal region expressed p63 (transitional/squamous cell marker, not detected in any normal pancreas or nonsquamous neoplasia) and the surface cells were positive for MUC 1 and MUC 6 (markers present in intercalated duct cells), and negative for GLUT-1 (consistent marker of serous adenomas).
  • The lesions appeared to be unilocular cystic dilatation of the ducts that typically contained distinctive muco-proteinaceous acidophilic acinar secretions forming concretions, confirming their communication with the acinar system, and suggesting a localized obstruction in their pathogenesis (a form of "retention" cyst).
  • These microcysts were found lying within compact acinar tissue, and appeared to be transforming from intercalated ducts, some focally connected to acinar elements, and they had abortive (nonbridging) septae with pseudo-loculated appearance, irregular contours and often showed tightly packed clusters of ducts with similar morphology described in the cases underwent resection specifically for this cyst type.
  • In conclusion, the distinctive morphologic, immunophenotypic, and clinical characteristics of this cystic lesion warrant its classification as a separate entity.
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Dilatation, Pathologic / metabolism. Dilatation, Pathologic / pathology. Dilatation, Pathologic / surgery. Female. Humans. Male. Middle Aged. Mucin-1. Mucin-6. Mucins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255775.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101936
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MUC1 protein, human; 0 / MUC6 protein, human; 0 / Mucin-1; 0 / Mucin-6; 0 / Mucins
  •  go-up   go-down


66. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatoblastoma is a very uncommon neoplasm in adults and its management represents a great challenge with regards to different treatment options.
  • CONCLUSION: Pancreatoblastoma is a rare neoplasm in adults.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • [MeSH-major] Carcinoma, Neuroendocrine. Pancreatic Neoplasms

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


67. Yamaguchi R, Okabe Y, Jimi A, Shiota K, Kodama T, Naito Y, Yasunaga M, Kinoshita H, Kojiro M: Pancreatic acinar cell carcinoma extending into the common bile and main pancreatic ducts. Pathol Int; 2006 Oct;56(10):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma extending into the common bile and main pancreatic ducts.
  • Acinar cell carcinoma (ACC) of the pancreas is relatively rare, accounting for only approximately 1% of all exocrine pancreatic tumors.
  • Magnetic resonance cholangiopancreatography showed defect of the lower common bile duct (CBD) due to obstruction by the tumor cast.
  • Histopathologically, the pancreatic head tumor invaded the main pancreatic duct (MPD) and CBD with extension into the CBD in a form of tumor cast.
  • The tumor cells consisted of a solid proliferation with abundant eosinophilic cytoplasm and round nuclei in an acinar and trabecular fashion.
  • Histopathologically, the tumor was encapsulated by fibrous capsule and had extensive central necrosis with solid areas in the tumor periphery, and invaded with extension into the MPD in a form of tumor cast.
  • The tumor cells resembled acinar cells in solid growths.
  • Two resected cases of ACC with unusual tumor extension into the CBD and the MPD, respectively, are reported.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Common Bile Duct / pathology. Common Bile Duct Neoplasms / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984622.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


68. Begnami MD, Quezado M, Pinto P, Linehan WM, Merino M: Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med; 2007 Apr;131(4):637-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate: review and update.
  • CONTEXT: Although most prostate carcinomas are of the conventional acinar type, unusual variants have been reported.
  • Adenoid cystic/basal cell carcinoma of the prostate is a rare tumor with distinctive histopathologic features.
  • There are only a few publications in the literature concerning the diagnosis, treatment, and prognosis of this neoplasm.
  • OBJECTIVE: To review current literature together with the clinical, pathologic, and immunohistochemical features of adenoid cystic/basal cell carcinoma of the prostate and offer a practical approach to the diagnosis--including the differential diagnosis--of this neoplasm in surgical pathologic specimens.
  • DATA SOURCES: Adenoid cystic/basal cell carcinoma of the prostate is composed of infiltrating basaloid cells forming dilated acinar and cribriform spaces with luminal basementlike material.
  • Differentiation of adenoid cystic/basal cell carcinoma from basal cell hyperplasia and cribriform pattern of acinar adenocarcinoma may be difficult.
  • CONCLUSIONS: Various histologic and immunohistochemical features are helpful in recognizing adenoid cystic/basal cell carcinoma of the prostate.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology


69. Ayub SB, Dodge J: Lipid-rich variant of pancreatic endocrine neoplasms: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):829-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid-rich variant of pancreatic endocrine neoplasms: a case report.
  • BACKGROUND: Pancreatic endocrine neoplasms (PENs) are a well-defined and well-characterized group of tumors.
  • The cells in the cell block were immunoreactive (positive) for cytokeratin AE1/AE3, synaptophysin, and chromogranin A.
  • An elective resection of the tumor was performed, which confirmed the diagnosis of lipid-rich variant of PENs.
  • CONCLUSION: Its mimickers include adrenal cortical carcinoma, metastatic clear-cell renal cell carcinoma, clear-cell PEN, foamy gland pattern of pancreatic ductal carcinoma, solid pseudopapillary tumor, and acinar cell carcinoma.
  • The distinguishing morphologic and immunohistochemical features of each are described.
  • [MeSH-major] Endocrine Gland Neoplasms / pathology. Lipids / chemistry. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053550.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Lipids
  •  go-up   go-down


70. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol; 2009 Sep;22(9):1176-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma.
  • Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7).
  • A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated.
  • TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively.
  • Interestingly, ERG rearrangement in small cell carcinomas occurred exclusively through Edel, supporting the notion that TMPRSS2:ERG with Edel is an aggressive molecular subtype.
  • Notably, 88% (43/49) variant morphologies in this cohort showed concordance of TMPRSS2:ERG fusion with associated conventional acinar type, suggesting that variant morphology is clonally related to the latter.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 1999;1(1):31-5 [11250680.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):316-27 [14976541.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):200-6 [17401460.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):781-6 [16901974.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Mod Pathol. 2007 Sep;20(9):921-8 [17632455.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] Urology. 2007 Oct;70(4):630-3 [17991527.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1690-5 [17971772.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):73-80 [18172298.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3094-8 [18451133.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3584-90 [18483239.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):519-28 [18538735.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7629-37 [18794152.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):381-95 [12549773.001]
  • (PMID = 19465903.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / U01 CA111275-01; United States / NCI NIH HHS / CA / R01 CA102872; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / UO1 CA111275-01; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / SPINK1 protein, human; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETV1 fusion protein, human
  • [Other-IDs] NLM/ NIHMS148618; NLM/ PMC2760291
  •  go-up   go-down


71. Díaz Sánchez A, Ponferrada Díaz A, Senosiain Labiano M, Huerta Madrigal A: [Upper digestive hemorrhage as the first manifestation of acinar cell carcinoma of the pancreas]. Gastroenterol Hepatol; 2006 Jun-Jul;29(6):380
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upper digestive hemorrhage as the first manifestation of acinar cell carcinoma of the pancreas].
  • [Transliterated title] Hemorragia digestiva alta como presentación de un carcinoma acinar pancreático.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Gastrointestinal Hemorrhage / etiology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Duodenal Neoplasms / diagnosis. Female. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790192.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


72. Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B: Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol; 2008 Jan;61(1):49-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry showed that TBX4 expression could be seen in both centroacinar cells and small ducts in normal pancreas and tumour cells in 5/5 (100%) well differentiated, 35/38 (92.1%) moderately differentiated, and 11/18 (61.1%) poorly differentiated PDAC tissues with different staining intensity.
  • However, in normal acinar cells and tumour cells in the other 3/38 (7.9%) moderately differentiated and 7/18 (38.9%) poorly differentiated PDAC tissues, there was no visible TBX4 expression.
  • In addition, there was obvious morphology difference between TBX4 negatively stained and positively stained tumour cells, which suggests different cellular origins.
  • Strong expression of HSP60 could be seen in both acinar cells and small ducts in normal pancreas tissues and tumour cells in PDAC tissues except for islets and tumour stoma; no correlation was found between HSP60 expression and differentiation of PDAC tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Female. HSP40 Heat-Shock Proteins / metabolism. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Pancreas / metabolism. Proteomics. T-Box Domain Proteins / metabolism. Trypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412869.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP40 Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / T-Box Domain Proteins; 0 / TBX4 protein, human; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


73. Lin J, Jing X: Fine-needle aspiration of intrapancreatic accessory spleen, mimic of pancreatic neoplasms. Arch Pathol Lab Med; 2010 Oct;134(10):1474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of intrapancreatic accessory spleen, mimic of pancreatic neoplasms.
  • Intrapancreatic accessory spleen (IPAS) is a congenital abnormality, which mimics neoplasm.
  • Distinguishing IPAS from pancreatic neoplasm/malignancy is extremely important from a treatment perspective.
  • The image findings were highly suggestive of a pancreatic endocrine neoplasm.
  • Hematoxylin-eosin–stained cell block sections showed conspicuous thin-walled blood vessels in addition to inflammatory cells.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Spleen / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Aged. Animals. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / ultrasonography. Coloring Agents. Diagnosis, Differential. Humans. Inflammation / pathology. Inflammation / ultrasonography. Lymphocytes / pathology. Lymphocytes / ultrasonography. Male. Pancreas / anatomy & histology. Pancreas / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923303.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


74. Frankel WL: Update on pancreatic endocrine tumors. Arch Pathol Lab Med; 2006 Jul;130(7):963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine tumors of the pancreas represent 1% to 2% of all pancreatic neoplasms.
  • The morphologic spectrum of these tumors can be variable, and the differential diagnosis includes chronic pancreatitis with neuroendocrine hyperplasia, ductal adenocarcinoma, solid pseudopapillary tumor, acinar cell carcinoma, and pancreatoblastoma.
  • It is important to be aware that unusual morphologic variants of pancreatic endocrine tumors are common, and immunohistochemical stains can help avoid misdiagnosis.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Diagnosis, Differential. Humans. Islets of Langerhans / pathology. Neoplasms, Germ Cell and Embryonal / diagnosis. Pancreatitis, Chronic / diagnosis. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831051.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


75. Azuma M, Ashida Y, Tamatani T, Motegi K, Takamaru N, Ishimaru N, Hayashi Y, Sato M: Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome. J Rheumatol; 2006 May;33(5):912-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome.
  • OBJECTIVE: Our previous study suggested that suppression by cepharanthin of tumor necrosis factor-a (TNF-a)-induced matrix metalloproteinase-9 (MMP-9) could prevent destruction of the acinar structure in the salivary glands of patients with Sjögren's syndrome (SS).
  • In this study, we observed that in vivo administration of cepharanthin prevented severe damage to acinar tissues in the murine model of human SS.
  • The apoptotic cell death of acinar cells was determined.
  • RESULTS: Although extensive mononuclear cell infiltration and destruction of acinar tissue in salivary and lacrimal glands were observed in control mice, significant improvement of these lesions was evident in mice treated with cepharanthin.
  • Immunohistochemical analysis revealed that p65, phosphorylated IkB-a, and MMP-9 were more strongly stained in the acinar cells of control mice than in cepharanthin-treated mice.
  • Although no staining for type IV collagen was observed in the acinar tissues of control mice, continuity of staining for type IV collagen was observed in acinar tissues of cepharanthin-treated mice.
  • Destruction of acinar tissues was attributed to the induction of apoptosis, suggesting that cepharanthin inhibits apoptosis by suppressing phosphorylation of IkB-a, followed by prevention of MMP-9 activation.
  • CONCLUSION: Our findings suggest that cepharanthin may be a promising agent for use in preventing destruction of acinar tissues in murine SS.
  • [MeSH-minor] Animals. Apoptosis. Benzylisoquinolines. Carrier Proteins / analysis. Collagen Type IV / analysis. Female. I-kappa B Proteins / analysis. Immunohistochemistry. Matrix Metalloproteinase 9 / analysis. Mice. Mice, Mutant Strains. Neoplasm Proteins / analysis. Transcription Factor RelA

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652422.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Benzylisoquinolines; 0 / Carrier Proteins; 0 / Collagen Type IV; 0 / I-kappa B Proteins; 0 / Neoplasm Proteins; 0 / Rela protein, mouse; 0 / Transcription Factor RelA; 139874-52-5 / NF-kappaB inhibitor alpha; 7592YJ0J6T / cepharanthine; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


76. Abiatari I, Gillen S, DeOliveira T, Klose T, Bo K, Giese NA, Friess H, Kleeff J: The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells. Int J Oncol; 2009 Nov;35(5):1111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perineural invasion of tumor cells is a characteristic feature of human pancreatic cancer.
  • MAPRE2 was predominately expressed in normal pancreatic acinar cells but absent in ductal cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Microtubule-Associated Proteins / biosynthesis. Neoplasm Invasiveness / genetics. Pancreatic Neoplasms / pathology. Peripheral Nerves / pathology
  • [MeSH-minor] Aged. Blotting, Western. Cell Line, Tumor. Female. Fluorescent Antibody Technique. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Male. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787265.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / RNA, Messenger
  •  go-up   go-down


77. Zharov VP, Galitovsky V, Chowdhury P: Nanocluster model of photothermal assay: application for high-sensitive monitoring of nicotine-induced changes in metabolism, apoptosis, and necrosis at a cellular level. J Biomed Opt; 2005 Jul-Aug;10(4):44011
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparison of PT responses of pancreatic tumor cells AR42J with isolated primary pancreatic acinar cells and HepG2 cells shows a universal nature of PT assay.
  • [MeSH-major] Microscopy, Fluorescence / methods. Models, Biological. Neoplasm Proteins / metabolism. Nicotine / administration & dosage. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. Thermography / methods
  • [MeSH-minor] Animals. Apoptosis / drug effects. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line. Cluster Analysis. Computer Simulation. Dose-Response Relationship, Drug. Humans. Image Interpretation, Computer-Assisted / methods. Male. Metabolic Clearance Rate / drug effects. Nanotechnology / methods. Necrosis. Photochemistry / methods. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178645.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097422; United States / NIBIB NIH HHS / EB / R01 EB 000873
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


78. Xu M, Yuan Y, Xia Y, Achilefu S: Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny. Clin Cancer Res; 2008 Nov 15;14(22):7461-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Targeting both CSCs and differentiated, rapidly proliferating tumor cells with therapeutic drugs provides a focused strategy to treat cancer.
  • We characterized mAb CC188 binding epitope and examined the epitope distribution in normal and tumor tissues, particularly in CSCs using tissue arrays and immunofluorescence staining method.
  • We also evaluated the effect of mAb CC188 on invasiveness of NSY tumor cells.
  • In contrast, the expression of the carbohydrate epitope was low in normal prostate muscle and pancreatic acinar cells, as well as in some normal epithelial cells of the breast duct, cervix, and skin.
  • A functional study indicated that mAb CC188 suppressed the invasiveness of NSY tumor cells.
  • CONCLUSION: mAb CC188 selectively targets a carbohydrate epitope expressed on cancer cells, providing a viable method for specific tumor imaging and targeted therapy.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antigens, Neoplasm / immunology. Carbohydrates / immunology. Colorectal Neoplasms / immunology. Epitopes, B-Lymphocyte / immunology. Neoplastic Stem Cells / immunology
  • [MeSH-minor] Antibody Specificity. Cell Differentiation. Cell Line, Tumor. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Immunomagnetic Separation. Neoplasm Invasiveness / immunology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010863.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109754; United States / NIBIB NIH HHS / EB / R01 EB1430; United States / NCI NIH HHS / CA / R21 CA123537
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Carbohydrates; 0 / Epitopes, B-Lymphocyte
  •  go-up   go-down


79. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • We then examined these two groups for the pathological stages of the neoplasms and the incidence of postoperative prostate-specific antigen (PSA) failure.
  • Seven of the cases (11%) were mixed-type ductal adenocarcinomas, which contained acinar and ductal components.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • [MeSH-major] Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


80. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R: Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas; 2010 Oct;39(7):972-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mayo Clinic experience with very rare exocrine pancreatic neoplasms.
  • OBJECTIVES: Limited data are available to guide the management of very rare exocrine neoplasms of the pancreas (VREP).
  • The most commonly identified neoplasms were acinar cell carcinoma (n = 15), small cell carcinoma (n = 12), and squamous cell carcinoma (n = 8).
  • [MeSH-major] Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy. Rare Diseases / mortality. Rare Diseases / therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Acinar Cell / mortality. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622706.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol; 2006 Nov;43(6):1008-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, this was a poorly demarcated, unencapsulated, multilobulated neoplasm that invaded surrounding perirectal skeletal muscle bundles.
  • Lobules were composed of sheets and acinar arrangements of cuboidal to round neoplastic epithelial cells with scant to moderate eosinophilic to amphophilic cytoplasm and a round or oval nucleus with coarse chromatin.
  • Acinar lumina sometimes contained eosinophilic proteinaceous material or cell debris.
  • This is the second report of this neoplasm in a cat.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Carcinoma / veterinary. Cat Diseases / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099161.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Imamura M, Kimura Y, Ito H, Nobuoka T, Koito K, Sasaki A, Hirata K: Acinar cell carcinoma of the pancreas with intraductal growth: report of a case. Surg Today; 2009;39(11):1006-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas with intraductal growth: report of a case.
  • Acinar cell carcinomas (ACCs) of the pancreas are rare neoplasms, accounting for approximately 1% of all exocrine pancreatic tumors.
  • This type of tumor is known to be aggressive, although the survival rates are somewhat better than they are for ductal carcinoma.
  • The tumor tends to present nonspecific symptoms.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Neoplasm Invasiveness. Pancreatectomy / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Surg Today. 2007;37(8):704-7 [17643220.001]
  • [Cites] Pancreas. 2003 Apr;26(3):306-8 [12657959.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jan;16(1):107-11 [11206307.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):410-6 [7459828.001]
  • (PMID = 19882327.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Mocan S, Stolnicu S, Rădulescu D, Petrovan C: [Acinic cell adenocarcinoma of the lip]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell adenocarcinoma of the lip].
  • [Transliterated title] Adenocarcinom cu celule acinare cu localizare la nivelul buzei. Prezentare de caz.
  • The variable histological appearance of acinic cell carcinoma coupled with its uncommon occurrence account for considerable diagnostic difficulties.
  • The tumour mass was excised, fixed in formaline, embedded in paraffin and the sections were stained with Haematoxylin-Eosin, PAS-Haematoxylin, PAS-Alcian blue and Perls.
  • The tumour was nodular, well circumscribed, with a cystic appearance on the cut surface.
  • Microscopically, the tumour had a papillary-cystic growth, with one large cystic space lined by epithelium of variable thickness and branching projections of epithelium occupying a large portion of the cyst's lumen.
  • Different cellular features were recognised in the tumour, with the presence of both serous and mucous acinar differentiation.
  • Acinic cell adenocarcinoma is a malignant epithelial neoplasm in which the neoplastic cells demonstrate not only serous acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607848.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


84. Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini PL, Forni G, Cavallo F, Musiani P: Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol; 2006 Jun 15;176(12):7695-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple acinar and ductal hyperplasia foci overexpressing the HER-2/neu gene product are evident at wk 5 and progress to poorly differentiated carcinoma by wk 7.
  • The most prominent immunologic features associated with the antitumor protection were the production of high titers of anti-HER-2/neu Abs and the nonappearance of cell-mediated cytotoxic reactivity.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Carcinoma / prevention & control. Cell Proliferation. Interleukin-12 / administration & dosage. Parotid Neoplasms / prevention & control. Receptor, ErbB-2 / genetics. Tumor Suppressor Protein p53 / genetics. Vaccines, DNA / administration & dosage
  • [MeSH-minor] 3T3 Cells. Animals. Antibodies, Neoplasm / biosynthesis. Cell Line, Tumor. Disease Progression. Female. Male. Mice. Mice, Inbred BALB C. Mice, Transgenic

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751417.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / Tumor Suppressor Protein p53; 0 / Vaccines, DNA; 187348-17-0 / Interleukin-12; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


85. Shah S, Mortele KJ: Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features. Semin Ultrasound CT MR; 2007 Oct;28(5):357-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, and magnetic resonance imaging features.
  • Various uncommon solid pancreatic neoplasms, including exocrine and endocrine epithelial tumors, mesenchymal tumors, and metastases, are reviewed, with emphasis on key differential points, including morphologic features and patterns of contrast enhancement.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / pathology. Contrast Media. Diagnosis, Differential. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / pathology. Humans. Lymphoma / diagnosis. Lymphoma / pathology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970552.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 41
  •  go-up   go-down


91. Pan Z, Erkan M, Streit S, Friess H, Kleeff J: Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. Int J Oncol; 2009 Oct;35(4):823-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we investigated the expression and the role of GRP94 in regulating cell growth and apoptosis in pancreatic cancer cells.
  • GRP94 protein was strongly expressed in normal acinar cells and moderately expressed in normal ductal cells.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Glycoproteins / metabolism. Pancreatic Neoplasms / metabolism. RNA Interference. RNA, Small Interfering / metabolism
  • [MeSH-minor] Cell Line, Tumor. Dactinomycin / pharmacology. Dose-Response Relationship, Drug. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Nucleic Acid Synthesis Inhibitors / pharmacology. Prognosis. Protein Synthesis Inhibitors / pharmacology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724918.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / endoplasmin; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


92. Neto AG, Pineda-Daboin K, Spencer ML, Luna MA: Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases. Head Neck; 2005 Jul;27(7):603-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal acinic cell carcinoma: a clinicopathologic study of four cases.
  • BACKGROUND: Acinic cell carcinoma is a low-grade malignant epithelial salivary gland neoplasm with a predilection for the parotid gland.
  • To date, only 11 cases of sinonasal acinic cell carcinomas have been reported in the English-language literature.
  • We present the clinicopathologic features of four sinonasal acinic cell carcinomas.
  • METHODS: The demographic data and pathologic material of four patients with sinonasal acinic cell carcinoma identified from the files of the Department of Pathology at The University of Texas M. D.
  • CONCLUSIONS: Sinonasal acinic cell carcinoma is a distinct low-grade carcinoma that can be distinguished from other neoplasms by light microscopy and histochemical staining methods.
  • Pathologists and surgeons should be aware of the occurrence of this type of salivary gland neoplasm in the sinonasal tract.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microscopy, Electron. Middle Aged. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900565.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


93. Adham M, Giunippero A, Hervieu V, Courbière M, Partensky C: Central pancreatectomy: single-center experience of 50 cases. Arch Surg; 2008 Feb;143(2):175-80; discussion 180-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications included 18 neuroendocrine tumors (11 nonfunctioning), 10 serous and 10 mucinous cystadenomas, 5 intraductal papillary mucinous neoplasms, 3 main pancreatic duct strictures, 2 solid cystic papillary tumors, 1 hydatid cyst, and 1 acinar cell carcinoma.
  • The mean length of the resected pancreas was 45 mm (range, 20-80 mm) and the mean tumor size was 23 mm (5-60 mm).
  • No patients developed de novo diabetes.
  • On long-term follow-up, 2 patients with invasive intraductal papillary mucinous neoplasia had recurrence; one was treated successfully by completion pancreatectomy and the other died at 20 months.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283143.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R: Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg; 2009 Aug;13(8):1495-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma: a multi-institutional study.
  • INTRODUCTION: The presentation and outcome of patients with acinar cell carcinoma (ACC) of the pancreas compared to the more common ductal cell adenocarcinoma (DCA) may be distinct.
  • Mean tumor size was 5.3 cm.
  • American Joint Commission on Cancer tumor stages were stage I (two), stage II (eight), stage III (four), and stage IV (three).
  • This is in contrast to 1,608 patients with ductal cell adenocarcinoma who underwent resection identified from recent literature reports where the average median survival was only 24 months.
  • CONCLUSION: Acinar cell carcinoma of the pancreas is rare and appears to have a presentation and outcome distinct from the more common pancreatic DCA.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Follow-Up Studies. Germany / epidemiology. Humans. Incidence. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Prospective Studies. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1127-8 [11473479.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Clin Imaging. 2006 Sep-Oct;30(5):343-6 [16919557.001]
  • [Cites] Gastroenterol Clin Biol. 2007 May;31(5):543-6 [17541347.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19327-32 [18042722.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1061-7 [17957440.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1403-4 [12045253.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Surgery. 2008 Aug;144(2):141-8 [18656619.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):498-504 [16891880.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Pancreas. 2003 Apr;26(3):306-8 [12657959.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2078-86 [18836784.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2673-81 [15024058.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • (PMID = 19495891.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


95. Kosmahl M, Pauser U, Anlauf M, Sipos B, Peters K, Lüttges J, Klöppel G: [Cystic pancreas tumors and their classification: features old and new]. Pathologe; 2005 Feb;26(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic tumors and tumor-like lesions of the pancreas are rare, but have attracted a great deal of attention because they are easily recognized with new imaging methods and, in contrast to ductal adenocarcinoma, they can usually be cured surgically.
  • Known entities have been better characterized (i.e. solid pseudopapillary neoplasm, intraductal papillary mucinous neoplasm) and new ones described (serous oligocystic adenoma, mucinous non-neoplastic cyst, acinar cell cystadenoma and cystic hamartoma).
  • This review discusses the most important cystic tumors and tumor-like lesions, presents a new classification, and summarizes the immunohistochemical differential diagnosis.
  • [MeSH-major] Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):113-5 [12004359.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):187-9 [9504865.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):154-8 [11850544.001]
  • [Cites] Ann Surg. 1978 Nov;188(5):679-84 [718294.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] Virchows Arch. 1994;424(1):13-7 [7526946.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Arch Pathol Lab Med. 2002 Feb;126(2):229-30 [11825129.001]
  • [Cites] Mod Pathol. 2002 May;15(5):492-501 [12011254.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1309-12 [1427759.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):698-704 [12023573.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1655-65 [1692551.001]
  • [Cites] Pancreas. 2000 Jul;21(1):104-5 [10881942.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Pancreas. 1996 May;12(4):419-21 [8740414.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):7-15 [10721803.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):1-6 [10721802.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Int Surg. 2000 Jan-Mar;85(1):67-70 [10817436.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):211-4 [12162680.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):916-21 [1785350.001]
  • [Cites] Ann Surg. 1975 May;181(5):546-51 [1130873.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):339-46 [15104296.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):317-21 [11141506.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1539-42 [8413476.001]
  • [Cites] Hum Pathol. 1992 Aug;23(8):871-5 [1644432.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1401-5 [8898845.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):6-13 [11499841.001]
  • [Cites] Am J Gastroenterol. 1982 Aug;77(8):576-7 [7102641.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • [Cites] Pathol Res Pract. 1996 Mar;192(3):300-4; discussion 305 [8739477.001]
  • (PMID = 15624092.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 58
  •  go-up   go-down


96. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K: Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol; 2007 Sep;52(3):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the prostate cancer incidence, anatomic distribution, Gleason score profile, and tumor burden in patients diagnosed by transperineal template-guided saturation biopsy (TTSB).
  • [MeSH-major] Biopsy / methods. Carcinoma, Acinar Cell / epidemiology. Prostatic Neoplasms / epidemiology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging / methods. Perineum. Predictive Value of Tests. Prostate-Specific Antigen / blood. Retrospective Studies. United States / epidemiology


97. Zhao J, Epstein JI: High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Am J Surg Pathol; 2009 Apr;33(4):583-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
  • The morphologic features of high foamy gland carcinoma have not been previously studied.
  • On average, 84% of the total tumor volume was foamy gland carcinoma, with high-grade foamy gland cancer averaging 73% of the total foamy gland carcinoma.
  • Concurrent ordinary acinar nonfoamy adenocarcinoma was encountered in 26 of 55 cases (47%) with the following Gleason scores: Gleason 6 (27%); Gleason 7 (27%); and Gleason 8 to 10 (46%).
  • Associated ordinary high-grade prostatic intraepithelial neoplasia and foamy gland variant of high-grade prostatic intraepithelial neoplasia/intraductal adenocarcinoma were seen in 13 cases (24%) and 11 cases (20%), respectively.
  • Of the 19 cases with available immunohistochemical stains for high molecular weight cytokeratin, 7 (37%) showed nonspecific labeling of cancer cells in a nonbasal cell pattern.
  • High-grade foamy gland cancer shares certain morphologic features with more typical lower-grade foamy gland cancer including relatively bland nuclei with more difficult to identify nucleoli and frequent intraluminal dense pink secretions.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Nucleolus / pathology. Humans. Keratin-7 / analysis. Male. Middle Aged. Mitosis. Neoplasm Invasiveness / pathology. Prostatic Intraepithelial Neoplasia / pathology. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033862.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-7
  •  go-up   go-down


98. Al-Zaher N, Obeid A, Al-Salam S, Al-Kayyali BS: Acinic cell carcinoma of the salivary glands: a literature review. Hematol Oncol Stem Cell Ther; 2009;2(1):259-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the salivary glands: a literature review.
  • Acinic cell carcinoma (ACC) is a low-grade malignant salivary neoplasm that constitutes approximately 17% of primary salivary gland malignancies.
  • The diagnosis is usually confirmed with a fine needle aspiration biopsy, and surgical excision is the main treatment of this malignant neoplasm.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063555.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


99. Susani M, Kenner L, Culig Z: [Diagnostic of prostate cancer: conventional and molecular or cell biological methods]. Pathologe; 2009 Dec;30 Suppl 2:154-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic of prostate cancer: conventional and molecular or cell biological methods].
  • In over 95% of cases an acinar "usual" form of prostate cancer is diagnosed but can be very different in characteristics and differentiation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Prostate / pathology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Humans. Interleukin-6 / genetics. Male. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prostate-Specific Antigen / analysis. Proto-Oncogene Proteins c-ets / analysis. Proto-Oncogene Proteins c-ets / genetics. Signal Transduction / genetics. Suppressor of Cytokine Signaling 3 Protein. Suppressor of Cytokine Signaling Proteins / analysis. Suppressor of Cytokine Signaling Proteins / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 Feb;448(2):111-8 [16328356.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):946-52 [15223967.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] Nat Genet. 2009 May;41(5):509-10 [19399032.001]
  • [Cites] Nat Genet. 2009 May;41(5):619-24 [19396168.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1921-30 [19342366.001]
  • [Cites] Eur J Cancer Prev. 2009 Sep;18(5):377-80 [19512934.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1310-9 [19297565.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Pathology. 2003 Dec;35(6):472-9 [14660096.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):497-511 [18563191.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1884-93 [12673714.001]
  • [Cites] J Urol. 2004 Mar;171(3):1093-7 [14767278.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Scand J Urol Nephrol. 2005;39(5):380-6 [16257839.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7375-84 [19738059.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • [Cites] N Engl J Med. 2009 Mar 26;360(13):1320-8 [19297566.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):378-83 [17595657.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • (PMID = 19802609.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Proto-Oncogene Proteins c-ets; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling 3 Protein; 0 / Suppressor of Cytokine Signaling Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 20
  •  go-up   go-down


100. Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM: Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. Mayo Clin Proc; 2009 Sep;84(9):801-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • OBJECTIVE: To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas.
  • PATIENTS AND METHODS: Between April 4, 2007, and December 4, 2008, interphase FISH was used to study paraffin-embedded preparations of tissue obtained from 18 patients listed in the Mayo Clinic Biospecimen Resource for Pancreas Research with a confirmed diagnosis of acinar cell carcinoma, ductal adenocarcinoma, islet cell carcinoma, or pancreas without evidence of neoplasia.
  • RESULTS: FISH abnormalities were observed in 12 (80%) of 15 patients with pancreatic cancer: 5 of 5 patients with acinar cell carcinoma, 5 of 5 patients with ductal adenocarcinoma, and 2 (40%) of 5 patients with islet cell carcinoma.
  • All 3 specimens of pancreatic tissue without neoplasia had normal FISH results.
  • Gains of CTNNB1 due to trisomy 3 occurred in each tumor with acinar cell carcinoma but in none of the other tumors in this study.
  • CONCLUSION: FISH abnormalities of CTNNB1 due to trisomy 3 were observed only in acinar cell carcinoma.
  • FISH abnormalities of genes implicated in familial cancer, tumor progression, and the 5-fluorouracil pathway were common but were not associated with specific types of pancreatic cancer.






Advertisement